

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number  
**WO 01/46260 A2**

(51) International Patent Classification<sup>7</sup>: C07K 16/00

(21) International Application Number: PCT/US00/34963

(22) International Filing Date:  
22 December 2000 (22.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/172,025 23 December 1999 (23.12.1999) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Lawrenceville-Princeton Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STARLING, Gary, Charles** [NZ/US]; 11 Gallo Court, Lawrenceville, NJ 08648 (US). **FINGER, Joshua** [US/US]; 197 North Union Street, Lambertville, NJ 08530 (US).

(74) Agents: **SHER, Audrey**; Bristol-Myers Squibb Company, P.O. Box 4000, Lawrenceville-Princeton Road, Princeton, NJ 08543-4000 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL IMMUNOGLOBULIN SUPERFAMILY MEMBERS APEX-1, APEX-2 AND APEX-3 AND USES THEREOF

## CD2 Subfamily Extracellular domains

**CD2 CD58 CD48 SLAM APEX-1 APEX-2 APEX-3**



• = potential N-linked glycosylation sites

(57) Abstract: The present invention provides the nucleotide and amino acid sequences of *apex-1*, -2, and 3, encoding novel APEX proteins APEX-1, APEX-2, and APEX-3, which are novel gene members of the CD2 subgroup of the immunoglobulin superfamily.



WO 01/46260 A2

**NOVEL IMMUNOGLOBULIN SUPERFAMILY MEMBERS APEX-1, APEX-2  
AND APEX-3 AND USES THEREOF**

5

10 Throughout this application, various publications are referenced. The disclosures of these publications in their entireties, are hereby incorporated by reference into this application, in order to more fully describe the state of the art, as known to those skilled therein, as of the date of invention, described and claimed herein.

15 **FIELD OF THE INVENTION**

The present invention relates to novel gene members encoding proteins of the immunoglobulin superfamily designated Antigen Presenting cell EXpression (APEX), including APEX-1, APEX-2, and APEX-3.

20

**BACKGROUND OF THE INVENTION**

The CD2 subgroup of the immunoglobulin (Ig) superfamily consists primarily of cell-surface receptors that regulate adhesion among different leukocytes and generate co-stimulatory signals. This subgroup consists of CD2 (LFA-2), CD58 (LFA-3), CD48, CD59, CD84, Ly9, 2B4, and CDw150 (SLAM). All Ig family members exhibit structural similarities including two or more extracellular Ig-like domains, a transmembrane domain or a glycosylphosphatidylinositol (GPI)-anchor moiety. Family members which span the membrane also have a cytoplasmic domain which may, or may not, have specific SH2 domain binding motifs. Members of this family mediate diverse biological events including leukocyte proliferation, differentiation, migration, and activation (Williams, A. F. and Barclay, A. N., 1988 *Ann. Rev. Immunol.* 6:381-405).

25  
30

CD2 was one of the first cell-adhesion molecules to be implicated in T-cell activation. In the early phase of the immune response, CD2 seems to facilitate antigen-independent activation and may be important in allowing the T-cell receptor (TCR) to sample different antigen-MHC complexes (Hahn, W. C., *et al* 1993 in: *Lymphocyte Adhesion Molecules* pp. 105-132, ed. Y. Shimizu, R. G. Landes Company). In addition to activation of both naive and memory T helper cells (Wingren, A. G., *et al* 1995 *Critical Reviews in Immunology* 15:235-253), interaction of CD2 with its ligand (mostly CD58 in humans, CD48 in rodents) results in the secretion of inflammatory cytokines (e.g. IL-1 and TNF). These inflammatory cytokines then recruit other immune cells to the site of injury or infection by upregulating adhesion molecule expression (Hahn, W. C., *et al*, 1993 in: *Lymphocyte Adhesion Molecules* pp. 105-132, ed. Y. Shmizu, R. G. Landes Company).

More recently, CD84, Ly9, 2B4 and SLAM have been shown to be structurally similar to the extracellular domains of CD2 family members, but contain slight differences (Angel de la Fuente, M., *et al*, 1997; Sandrin, M. S., *et al*, 1996; Cocks, B. G., *et al*, 1995). CD84 and SLAM each contain a V-set domain which lacks the usually conserved cysteine residues while the second domain is a truncated C2-set (tC2) domain containing conserved cysteine residues. Ly9 contains four Ig-like domains of the order V-tC2-V-tC2. All three molecules contain a cytoplasmic domain consisting of several SH2 domain binding motifs of the primary structure Y-X-X-hydrophobic (Songyang, Z., *et al* 1993 *Cell* 72:767-778). When these tyrosine residues are phosphorylated, they may become potential docking sites for kinases or other proteins. These kinases can act to phosphorylate other proteins and subsequently activate gene transcription. SLAM and 2B4 contain a motif T-X-Y-X-X-I/V, which is thought to be responsible for binding to SHP-2 kinase (Tangye, S. G., *et al* 1999 *J. Immunol.* 162:6981-6985). 2B4 is a receptor which positively regulates the activity of natural killer cells. Recent work has shown that 2B4 is a ligand for CD48 (Brown *et al.* 1998 *J. Exp. Med.* 188:2083-2090), further demonstrating that members of this family of molecules are able to bind to other members of this family.

CD84, Ly9, and SLAM expression is predominantly restricted to hematopoietic tissues with highest levels in the spleen, lymph node and peripheral blood leukocytes (PBL). SLAM is expressed on activated T cells and immature thymocytes (Cocks, B. G., *et al*  
5 1995 *Nature* 376:260-263), and is also found on activated antigen presenting cells (APCs).

CD84 and Ly9 functions have not been elucidated to date. SLAM, on the other hand, has been shown to enhance antigen-specific proliferation and cytokine production by CD4+ T  
10 cells. Specifically, antibodies against SLAM strongly upregulate IFN- $\gamma$  in both Th1 and Th2 clones, but do not induce IL-4 and IL-5 in Th1 clones. In addition, SLAM potentiates T-cell expansion in a CD28-independent manner (Cocks, B. G., *et al* 1995 *Nature* 376:260-263).

15 The present invention relates to the discovery of three new APEX protein members of the Ig superfamily, APEX-1, -2 and -3. The predicted products of the new *apex-1*, *apex-2*, and *apex-3* Ig genes show homology to the CD2 subgroup, and may be classified as a marker of that subgroup, based on sequence homology.

## 20 SUMMARY OF THE INVENTION

The acronym "APEX" or "*apex*" stands for Antigen Presenting cell EXpression, although the transcript expression pattern of the *apex* genes is not restricted to APCs. For convenience, the italicized term *apex* refers herein to an *apex* nucleic acid molecule or  
25 nucleotide sequences (gene). The capitalized term APEX refers herein to an APEX polypeptide (protein).

The present invention provides three novel nucleic acid molecules, designated *apex-1*, *apex-2*, and *apex-3*, and fragments and derivatives thereof (e.g. mutants, variants,  
30 homologues), having APEX activity, each having a nucleotide sequence which encodes a new APEX protein member of the immunoglobulin superfamily. In a particular aspect,

*apex-1* is described by SEQ ID NO: 1; *apex-2* is described by SEQ ID NO: 2; and *apex-3* is described by SEQ ID NO: 3.

5 In addition, the invention features nucleotide sequences that hybridize under stringent conditions to SEQ ID NO: 1, 2, or 3. The nucleic acid molecules of the invention further include portions of the *apex* sequences, such as fragments, oligonucleotides, or portions thereof, and peptide nucleic acids (PNA), and antisense molecules thereof which may be used to detect levels of *apex* transcripts that occur in a cell.

10 The invention provides isolated nucleic acid molecules and recombinant nucleic acid molecules having the *apex* sequences of the invention, and methods for uses thereof. The invention further provides isolated polypeptides and recombinant polypeptides having the APEX sequences of the invention, and methods for uses thereof.

15 The invention also provides isolated and substantially purified polypeptides APEX-1, APEX-2, and APEX-3. The invention further provides diagnostic assays and kits for the detection of naturally occurring APEX-1, -2 or -3 or the nucleic acids encoding them. It provides for the use of substantially purified APEX-1, -2 or -3 to produce antibodies reactive against an APEX protein, which can be used to quantitate the amount of APEX  
20 proteins in biological samples, e.g., in biological fluids or biopsied tissues from a subject.

These APEX proteins can also be used to produce antagonists which will bind to APEX molecules on the surface of tumor cells *in vivo* or *in vitro*, and as molecular weight markers. Substantially purified APEX proteins, or their fragments having APEX activity,  
25 may be useful as pharmaceutical compositions. For example, they may be used to inhibit cell adhesion.

The invention also relates to pharmaceutical compositions comprising antisense molecules capable of disrupting expression of *apex* genomic sequences, and agonists,  
30 antibodies, antagonists or inhibitors of the APEX proteins. These compositions are

useful for the prevention or treatment of conditions associated with the presence or the expression of APEX proteins.

#### BRIEF DESCRIPTION OF THE FIGURES

5

Figure 1: A schematic representation of the general structure of the extracellular domains of the CD2 subgroup.

Figure 2: The nucleotide sequence of *apex-1* (SEQ ID NO: 1).

10

Figure 3: The nucleotide sequence of *apex-2*. A portion of the nucleotide sequence of *apex-2*, beginning at thymine (t) at nucleotide 50 and ending at thymine (t) at nucleotide 1565 of Figure 2 is shown in SEQ ID NO: 2.

15 

Figure 4: The nucleotide sequence of *apex-3* (SEQ ID NO: 3).

Figure 5: The amino acid sequence of APEX-1 protein (SEQ ID NO: 4).

Figure 6: The amino acid sequence of APEX-2 protein (SEQ ID NO: 5).

20

Figure 7: The amino acid sequence of APEX-3 protein (SEQ ID NO:6).

Figure 8: A and B: A Northern blot showing the detection of *apex-1* transcripts in immune and non-immune tissues, as described in Example 1.

25

Figure 9: A RT-PCR analysis showing detection of *apex-1* transcripts in various cell types, as described in Example 1.

30

Figure 10: The amino acid sequence of the extracellular domain of APEX-1 in the fusion protein APEX-1Ig. The predicted signal sequence (Met<sub>1</sub> to Ala<sub>22</sub>) is shown in bold. The sequence from Ser<sub>23</sub> to Ser<sub>225</sub> corresponds to the extracellular domain of human APEX-1.

The junction His<sub>226</sub> to Pro<sub>227</sub> sequence results from the BamHI restriction site and is followed by a sequence corresponding to the H-CH<sub>2</sub>-CH<sub>3</sub> sequence from human IgG1.

Figure 11: The amino acid sequence of the extracellular domain of APEX-2 in the fusion protein APEX-2mIg. The predicted signal sequence (Met<sub>1</sub> to Gly<sub>29</sub>) is shown in bold and is expected to be cleaved in the mature protein. The sequence from Ser<sub>30</sub> to Trp<sub>238</sub> corresponds to the extracellular domain of murine APEX-2. The junction His<sub>239</sub> to Pro<sub>240</sub> sequence results from the BamHI restriction site and is followed by a sequence corresponding to the H-CH<sub>2</sub>-CH<sub>3</sub> sequence of murine IgG2a.

Figure 12: The SDS-PAGE of APEX-1Ig and APEX-2mIg fusion proteins, as described in Example 4. Proteins were run on a 12% Tris-Glycine gel under reducing conditions, and proteins visualized using coomassie blue staining.

Figure 13: The SDS-PAGE of APEX-1Ig fusion protein expressed in COS and Sf9 cells, as described in Example 4.

Figure 14: Western Blot analysis of the APEX-1 extracellular domains using a panel of anti-APEX-1 mAb, as described in Example 4. The mAbs were immunoblotted against the recombinant extracellular domain of APEX-1 under reducing and non-reducing conditions as shown.

Figure 15: The amino acid sequence of fusion protein FLAG-APEX-1. The Met<sub>1</sub> to Gly<sub>24</sub> sequence is from human CD5 signal peptide and is expected to be cleaved in mature protein. The Asp<sub>25</sub> to Lys<sub>32</sub> sequence corresponds to the FLAG peptide sequence.

Figure 16: The amino acid sequence of fusion protein FLAG-APEX-2. The Met<sub>1</sub> to Gly<sub>24</sub> sequence is from human CD5 signal peptide and is expected to be cleaved in mature protein. The Asp<sub>25</sub> to Lys<sub>32</sub> sequence corresponds to the FLAG peptide sequence.

## DETAILED DESCRIPTION OF THE INVENTION

### MOLECULES OF THE INVENTION

5 In its various aspects, as described in detail below, the present invention provides APEX proteins, *apex* nucleic acid molecules (including *apex* nucleotide sequences, genomic and cDNA), recombinant DNA molecules, transformed host cells, generation methods, assays, antibodies, immunotherapeutic methods, transgenic animals, immunological and nucleic acid-based assays, and compositions.

10

For the sake of convenience, nucleic acid molecules having *apex* nucleotide sequences will be collectively referred to as the *apex* sequences, the nucleotide sequences of the invention, or *apex*. Additionally, APEX proteins will be collectively referred to as the APEX proteins, the proteins of the invention, or APEX.

15

#### Nucleic Acid Molecules

The present invention discloses the discovery of novel *apex* nucleotide sequences which encode full-length APEX polypeptides or fragments thereof which possess structural  
20 features shared with the CD2 subgroup (e.g., see Figure 1) and are predicted to encode new members of the immunoglobulin superfamily. The structural features shared by the CD2 subgroup include a N-terminal signal peptide, an extracellular domain or region having Ig-like features, a hydrophobic transmembrane domain, and a C-terminal intracellular or cytoplasmic domain (e.g., see Figure 1). Thus, similar to CD2 members,  
25 the APEX proteins may play a role as cell-surface receptors that regulate adhesion among different leukocytes and generate co-stimulatory signals.

One embodiment of the invention provides nucleic acid molecules that are DNA or RNA. Another embodiment provides nucleic acid molecules that exhibit significant sequence  
30 identity with the *apex* nucleotide sequences of the invention, such as molecules that have between about 60% to 99% sequence identity with the *apex* sequences of the invention.



A preferred embodiment provides nucleic acid molecules that exhibit about 60% sequence identity, a more preferred embodiment provides molecules that have about 85% sequence identity, and the most preferred embodiment provides molecules that have about 95% to 99% sequence identity with the *apex* sequences of the invention.

5 Accordingly, the present invention encompasses *apex* from any species, e.g., human, mouse and other mammals. The present invention also encompasses different alleles of the *apex* gene isolated from different subjects of the same mammalian species.

"Nucleotide sequences" as used herein refers to an oligonucleotides, or nucleotides, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which

10 may be single- or double-stranded, and represents the sense or antisense strand.

"Peptide nucleic acid" (PNA) as used herein refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been

15 added. These small molecules, also designated anti-sense and anti-gene agents, stop transcript elongation by binding to their complementary (template) strand of nucleic acid (Nielsen, P. E., et al., 1993) *Anticancer Drug Des.* 8:53-63).

As used herein, a nucleic acid molecule is said to be "isolated" when the nucleic acid molecule is substantially separated from contaminant nucleic acid molecules having

20 sequences other than *apex* sequences. Additionally, isolated nucleic acid molecule refers to any RNA or DNA sequence, however constructed or synthesized. A skilled artisan can readily employ nucleic acid isolation procedures to obtain an isolated *apex*-encoding nucleic acid molecule, see Sambrook *et al.*, *Molecular Cloning* (1989).

25 The nucleic acid molecules of the invention are preferably in isolated form, including DNA, RNA, DNA/RNA hybrids, and related molecules, nucleic acid molecules complementary to the APEX coding sequences or a part thereof, and those which hybridize to the nucleic acid sequences that encode the APEX proteins. The preferred

30 nucleic acid molecules have a nucleotide sequence substantially identical to or complementary to the cDNA sequences herein disclosed. Specifically contemplated are

genomic DNA, ribozymes, and antisense molecules, as well as nucleic acids based on an alternative backbone or including alternative bases, whether derived from natural sources or synthesized.

5 The invention further provides fragments of the APEX-encoding nucleic acid molecules of the present invention. As used herein, a fragment of an APEX-encoding nucleic acid molecule refers to a portion of the entire APEX-encoding sequence. The size of the fragment will be determined by its intended use. For example, if the fragment is chosen to encode an APEX-encoding extracellular domain, then the skilled artisan shall select  
10 the nucleotide fragment that is large enough to encode this functional domain(s) of the APEX protein. If the fragment is to be used as a nucleic acid probe or PCR primer, then the fragment length is chosen so as to minimize the number of false positives during probing or priming.

The present invention provides specific nucleic acid molecules encoding proteins  
15 designated APEX-1, -2, and -3 or fragments thereof having APEX activity. One embodiment encompassed by the present invention includes isolated nucleotide sequences of *apex*-1, -2, -3, as described in, e.g., SEQ ID NO.: 1, 2, or 3, respectively, or portions thereof. In particular, the nucleic acid molecules of the invention may be isolated full-length or partial cDNA molecules or oligomers of the *apex* -1, -2, or -3 sequences.  
20 The nucleic acid molecules of the invention each include the nucleotide sequences encoding all or portions of the signal peptide region, the extracellular domain, the transmembrane domain, and/or the intracellular domain of APEX -1, -2 or -3.

In one embodiment, *apex*-1 sequence as shown in SEQ ID NO. 1, comprises the coding  
25 sequence for APEX-1 protein between nucleotides 42 and 1049. The 1008 base pair coding sequence within *apex*-1 beginning at adenine (a) at position 42 and ending at guanine (g) at position 1049 can encode a 335 amino acid APEX-1 protein. The APEX-1 protein is comprised of a signal peptide, an extracellular domain, a transmembrane domain, and a cytoplasmic domain (Figure 2).

30

In another embodiment, *apex-2* sequence as shown in SEQ ID NO. 2, comprises the coding sequence of APEX-2 protein between nucleotides 162 and 1217. The 1056 base pair coding region of *apex-2* beginning at adenine (a) at position 162 and ending at adenine (a) at position 1217 as shown in SEQ ID NO.2 can encode a 351 amino acid APEX-2 protein. The APEX-2 protein is comprised of a signal peptide, an extracellular domain, a transmembrane domain, and a cytoplasmic domain (Figure 3).

In another embodiment, *apex-3* sequence as shown in SEQ ID NO. 3, comprises the coding sequence of APEX-3 protein between nucleotides 115 and 972. The 868 base pair coding region of *apex-3* beginning at adenine (a) at position 115 and ending at adenine (a) at position 972 as shown in SEQ ID NO. 3 can encode a 285 amino acid APEX-3 protein. The APEX-3 protein is comprised of a signal peptide, an extracellular domain, a transmembrane domain, and a cytoplasmic domain (Figure 4).

The nucleic acid molecules of the invention may be recombinant DNA molecules each comprising the sequence of *apex -1, -2 or -3* (or fragments or derivatives thereof) fused to non-*apex* sequences, such as human Ig or FLAG: DYKDDDDK (Sigma-Aldrich Corporation, St. Louis, MO), which is a commercially available 8 amino acid sequence tag. Reviews of methods for synthesis of oligonucleotides can be found in: *Oligonucleotides and Analogues*, eds. F. Eckstein, 1991, IRL Press, New York; *Oligonucleotide Synthesis*, ed. M. J. Gait, 1984, IRL Press, Oxford, England.

The present invention also provides uses of the *apex* nucleotide sequences and their corresponding amino acid sequences, and antibodies reactive against the APEX proteins for the study, diagnosis, prevention and treatment of disease associated with the presence of an APEX protein.

#### **Fragments of *apex***

*Apex* e.g., *apex-1, -2, and -3*, includes fragments can be used as selective hybridization probes or PCR primers. These fragments can be readily identified from the entire sequence

of the APEX proteins, using art-known methods. A "primer" is a nucleic acid fragment which functions as an initiating substrate for enzymatic or synthetic elongation of, for example, a nucleic acid molecule. For example, sets of PCR primers that are useful for detecting transcripts encoding the extracellular domain of an APEX protein comprise the forward primer JNF6 (5' - atc ctt tgg cag ctc aca gg -3'; SEQ ID NO.: 12) and the reverse primer JNF7 (5'-ctt cac aga gct tcc tgg c-3'; SEQ ID NO.: 13).

### Complementary Sequences

The nucleic acid molecules provided by the present invention include DNA molecules each comprising the nucleotide sequence, or portions thereof, which are complementary to the nucleotide sequences as described in e.g. SEQ ID NO.: 1, 2, or 3.

The term "complementary" as used herein refers to the capacity of purine and pyrimidine nucleotides to associate through hydrogen bonding to form double stranded nucleic acid molecules. The following base pairs are related by complementarity: guanine and cytosine; adenine and thymine; and adenine and uracil. Complementary applies to all base pairs comprising two single-stranded nucleic acid molecules.

The present invention also provides complementary nucleic acid molecules having various degrees of sequence similarity with the *apex* sequences, which are exactly complementary to SEQ ID NO. 1, SEQ ID NO.2, or SEQ ID NO. 3. For example, nucleotide sequences that are substantially similar to the exact complementary *apex* sequences or portions thereof, will hybridize to an *apex-1*, -2 or -3 sequence under high stringency hybridization conditions. Typically, hybridization under standard high stringency conditions will occur between two nucleic acid molecules that differ in sequence by about 80% to about 99%. It is readily apparent to one skilled in the art that the high stringency hybridization between nucleic acid molecules depends upon, for example, the degree of similarity, the stringency of hybridization, and the length of hybridizing strands. The methods and formulas for conducting high stringency

hybridizations are well known in the art, and can be found in, for example, Sambrook *et al.*, *Molecular Cloning* (1989).

#### **Allelic Forms Of *apex***

5

The present invention provides nucleotide sequences of cDNA encoding allelic forms of *apex*. For example, one allelic form of human *apex*-1 is described in Figure 2 (SEQ ID NO.: 1). The nucleotide sequence of a cDNA encoding one allelic form of murine *apex*-2 is described in Figure 3 (SEQ ID NO.: 2), and the nucleotide sequence of a cDNA encoding one allelic form of human *apex*-3 is described in Figure 4 (SEQ ID NO.: 3). As used herein, an "allele" or "allelic sequence" is an alternative form of the *apex* gene. Alleles result from a mutation, such as, a change in the nucleotide sequence, and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered. The present invention contemplates other allelic forms of nucleic acid molecules encoding *apex*-1, -2 and -3 that are isolated from different subjects of the same species. Identification of allelic variants is known in the art.

10  
15

#### **Homologues**

The present invention provides nucleotide sequences that encode APEX homologues. For example, the invention provides the human homologue of APEX-1 and -3, and the murine homologue of APEX-2. One embodiment of the invention also provides the nucleotide sequences of *apex*-1, -2, and -3 homologues isolated from other species. Protein homologues from different species are related as a result of common ancestry. The ancestral homologue may have undergone speciation (e.g., an ortholog) or gene duplication (e.g., a paralog). Thus, protein homologues are typically isolated from different species and have the same or similar function. As a result of the common ancestry, homologues may or may not have similar amino acid sequences. The homologues can be from any species particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human. Methods for the identification of APEX

20  
25  
30

homologues are routine and well known in the art (Sambrook et al., *Molecular Cloning* (1989)).

### Variant Nucleotide Sequences

5

It may be advantageous to generate codon-usage variants that are altered from the disclosed *apex* nucleotide sequences, yet do not alter the amino acid sequence of the encoded APEX proteins. The codons may be selected to optimize the level of production of the *apex* transcript or APEX protein in a particular prokaryotic or eukaryotic expression host, in accordance with the frequency of codon utilized by the host cell. Alternative reasons for altering the nucleotide sequence encoding an APEX protein include the production of RNA transcripts having more desirable properties, such as an increased half-life. A multitude of variant *apex* nucleotide sequences that encode the respective APEX proteins may be isolated, as a result of the degeneracy of the genetic code. Accordingly, the present invention contemplates selecting every possible triplet codon to produce every possible combination of nucleotide sequences that encode the disclosed amino acid sequence of APEX-1, -2 or -3 proteins. One embodiment of the present invention provides isolated nucleotide sequences that vary from the sequences as described in SEQ ID NO.: 1, 2, or 3, such that each variant nucleotide sequence encodes a polypeptide having sequence identity with the amino acid sequence of APEX-1, -2, or -3, as described in SEQ ID NO.: 4, 5, or 6, respectively.

10  
15  
20

### RNA

The present invention provides RNA molecules that encode APEX proteins. In particular, the RNA molecules of the invention may be isolated full-length or partial mRNA molecules, or RNA oligomers that encode APEX -1, -2, or -3. The RNA molecules of the invention each include the nucleotide sequences encoding all or portions of the signal peptide region, the extracellular domain, the transmembrane domain, and/or the intracellular domain of APEX -1, -2 or -3.

25  
30

The RNA molecules of the invention also include antisense RNA molecules, peptide nucleic acids (PNAs), or non-nucleic acid molecules such as phosphorothioate derivatives, that specifically bind to the sense strand of DNA or RNA in a base pair-dependent manner. A skilled artisan can readily obtain these classes of nucleic acid molecules using the herein described *apex* sequences.

### Peptide Nucleic Acids

The nucleic acid molecules of the invention include peptide nucleic acids (PNAs), or derivative molecules such as phosphorothioate, phosphotriester, phosphoramidate, and methylphosphonate, that specifically bind to single-stranded *apex* DNA or RNA in a base pair-dependent manner (P. C. Zamecnik, et al., 1978 *Proc. Natl. Acad. Sci.* 75:280284; Goodchild, P. C., et al., 1986 *Proc. Natl. Acad. Sci.* 83:4143-4146). A skilled artisan can readily obtain these classes of nucleic acid molecules using the herein described *apex* sequences. For example, reviews of methods for synthesis of DNA, RNA, and their analogues can be found in: *Oligonucleotides and Analogues*, eds. F. Eckstein, 1991, IRL Press, New York; *Oligonucleotide Synthesis*, ed. M. J. Gait, 1984, IRL Press, Oxford, England. Additionally, methods for antisense RNA technology are described in U. S. patents 5,194,428 and 5,110,802.

20

A PNA molecule comprises a nucleic acid oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated anti-gene agents stop transcription elongation by binding to the complementary strand of nucleic acid (Nielsen, P. E. et al. 1993 *Anticancer Drug Des*, 8:53-63). A skilled artisan can readily obtain these classes of nucleic acid molecules using the herein described modified *apex* nucleotide sequences, see for example *Innovative and Perspectives in Solid Phase Synthesis* (1992) Egholm, et al. pp 325-328 or U. S. Patent No. 5,539,082.

25

### **Nucleic Acid Molecules Labeled With A Detectable Marker**

Embodiments of the APEX-encoding nucleic acid molecules of the invention include DNA and RNA primers, which allow the specific amplification of nucleic acid molecules of the invention or of any specific parts thereof, and probes that selectively or specifically hybridize to nucleic acid molecules of the invention or to any part thereof. The nucleic acid probes can be labeled with a detectable marker. Examples of a detectable marker include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator or an enzyme. Technologies for generating labeled DNA and RNA probes are well known.

### **APEX PROTEINS AND POLYPEPTIDES**

APEX proteins of this invention belong to the Ig superfamily and may be involved in ligand binding and signal transduction. The predicted sequence of APEX proteins includes a N-terminal hydrophobic signal peptide, an extracellular domain consisting of two Ig-like regions, a transmembrane domain, and an intracellular domain (for description, See Examples 1-3). APEX proteins can be full length or fragments thereof that have APEX activity.

20

In one embodiment, the APEX-1 protein includes a N-terminal 22 amino acid hydrophobic signal peptide, a 203 amino acid extracellular domain, a 24 amino acid transmembrane domain, and an 86 amino acid intracellular domain (see Figure 5). APEX-1 is encoded by nucleotide sequence 42 to 1049 as shown in SEQ ID NO. 1. Further, APEX-1 includes an extracellular domain. The extracellular domain of APEX-1 can be encoded by, for example, nucleotide sequence 108-716 as shown in SEQ ID NO. 1.

25

In another embodiment, APEX-2 protein comprises a putative signal peptide of 29 amino acids, a 210 amino acid extracellular domain, a 23 amino acid transmembrane domain, and an 89 amino acid cytoplasmic domain (see Figure 6). APEX-2 is encoded by

30



nucleotide sequence 162 to 1217 as shown in SEQ ID NO. 2. Further, APEX-2 includes an extracellular domain. The extracellular domain of APEX-2 can be encoded by, for example, nucleotide sequence 249 to 875 as shown in SEQ ID NO. 2.

- 5 In yet another embodiment, APEX-3 comprises a 22 amino acid signal peptide, a 209 amino acid extracellular domain, a 23 amino acid transmembrane domain, and a 31 amino acid cytoplasmic domain (Figure 7). The putative cytoplasmic domain of APEX-3 is much shorter than the cytoplasm of other CD2 subgroup members. APEX-3 is encoded by, for example, nucleotide sequence 115 to 972 as shown in SEQ ID NO. 3.

10

- APEX proteins share structural similarities with members of the CD2 subfamily. Thus, it is postulated that APEX proteins represent a family of cell-surface receptors that regulate adhesion and generate co-stimulatory signals to mediate leukocyte proliferation, differentiation, migration, or activation. It is possible that APEX proteins enhance  
15 antigen-specific proliferation and cytokine production, similar to SLAM which is another member of the CD2 subfamily. Thus, APEX proteins may prove to be a potential target for diseases with an inflammatory and autoimmune component.

- As used herein, APEX proteins of this invention include a protein that has the amino acid  
20 sequence of human APEX-1 as provided in Figure 5 (e.g., SEQ ID NO.: 4), the amino acid sequence of murine APEX-2 as provided in Figure 6 (e.g., SEQ ID NO.: 5), the amino acid sequence of human APEX-3 as provided in Figure 7 (SEQ ID NO.: 6), or other mammalian APEX homologues, as well as allelic variants and conservative substitution mutants of these proteins, that have structural similarities to APEX proteins of the invention, or APEX  
25 activity or function. One aspect of the invention provides various APEX proteins and peptide fragments thereof having APEX activity. For the sake of convenience, all APEX proteins will be collectively referred to as the APEX proteins, the proteins of the invention, or APEX.

- 30 As used herein, "APEX" refers to the amino acid sequence of APEX polypeptides from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine,

and preferably human, in a naturally occurring form or from any source whether natural, synthetic, semi-synthetic or recombinant. As used herein, "naturally occurring" refers to an amino acid sequence which is found in nature.

- 5 The term "having APEX activity" refers to an APEX protein or fragment having a function of the naturally occurring APEX and/or ability to recognize and bind ligands or antibodies directed against APEX. The term "APEX activity" further defines the capability to induce a specific immune response in appropriate animals or cells and to bind with specific APEX antibodies.

10

The term "derivative" as used herein refers to a chemical modification of the *apex* nucleic acid molecule or the encoded APEX protein. Illustrative of such modifications of an APEX protein would be replacement of hydrogen by an alkyl, acyl, or amino group. An APEX derivative would encode a polypeptide which retains the essential biological characteristics and activities of natural APEX.

15

#### **Variant Polypeptides and Proteins**

- The present invention provides APEX proteins including all isolated, naturally occurring or recombinantly made allelic variants; isoforms, and precursors of human APEX-1 or -3 as provided in Figures 5 and 7, respectively; and murine APEX-2 as provided in Figure 5. In general, for example, naturally occurring allelic variants of human or murine APEX will share significant homology (e.g., about 70 - 99%) to the APEX amino acid sequences provided in Figures 5, 6, and 7. Allelic variants, though possessing a slightly different amino acid sequence, may be expressed on the surface of APCs cells or may be secreted or shed.

20

25

- Typically, allelic variants of the APEX protein can include one or more conservative amino acid substitutions from the APEX sequence herein described or will include a substitution of an amino acid from a corresponding position in an APEX homologue such as, for example, the murine APEX homologue described herein.

30

One type of allelic variant of *apex* encodes APEX proteins having amino acid sequences with one or more amino acid substitutions, insertions, deletions, truncations, or frame shifts. Such alleles are termed mutant alleles of APEX and represent proteins that may or may not  
5 perform the same biological functions as wild-type APEX, such as function as a cell-surface receptor.

Another variant of APEX may have an amino acid sequence that is different by one or more amino acid "substitutions". The variant may have "conservative" changes, wherein  
10 a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. Alternatively, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted may be found  
15 using computer programs well known in the art, for example, DNASTAR software.

Conservative amino acid substitutions can frequently be made in a protein without altering either the conformation or the function of the protein. Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these  
20 hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable,  
25 as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered  
30 "conservative" in particular environments.

APEX proteins may be embodied in many forms, preferably in isolated form. As used herein, a protein is said to be isolated when physical, mechanical or chemical methods are employed to remove the APEX protein from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification  
5 methods to obtain an isolated APEX protein, see for example *Strategies for Protein Purification and Characterization* (1996) pp 396, Marshak, D. R. et al.

A purified APEX protein molecule will be substantially free of other proteins or molecules that impair the binding of APEX to antibody or other ligand. The nature and  
10 degree of isolation and purification will depend on the intended use. Embodiments of the APEX protein include a purified APEX protein, or fragment thereof having APEX activity. Examples of a purified APEX protein include proteins having the amino acid sequence shown in Figures 5, 6, or 7, or a fragment thereof. In one form, such purified APEX proteins, or fragments thereof, retain the ability to bind antibody or other ligand.

15 The term "purified" as used herein means a specific isolated nucleic acid molecule or protein, or fragment thereof, in which substantially all contaminants (i.e. substances that differ from said specific molecule) have been separated from said nucleic acid molecule or protein. For example, a protein may, but not necessarily, be "substantially purified" by  
20 the immuno affinity column chromatography (IMAC) method.

### Peptides

APEX proteins and APEX proteins and peptide fragments of APEX having APEX activity  
25 can be generated using standard peptide synthesis technology and the amino acid sequences of the human or murine APEX proteins disclosed herein. The principles of solid phase chemical synthesis of polypeptides are well known in the art and may be found in general texts relating to this area (H. Dugas and C. Penney, 1981 in: *Bioorganic Chemistry*, Springer-Verlag, New York, pp 54-92). The polypeptides of the invention may be  
30 synthesized by solid-phase methodology utilizing an Applied Biosystems 430A peptide synthesizer (Applied Biosystems, Foster City, Calif.) and synthesis cycles supplied by

Applied Biosystems. Protected amino acids, such as t-butoxycarbonyl-protected amino acids, and other reagents are commercially available from many chemical supply houses.

Alternatively, recombinant methods can be used to generate nucleic acid molecules that  
5 encode a fragment of the APEX protein having the sequence and /or activity of APEX protein. In this regard, the APEX-encoding nucleic acid molecules described herein provide means for generating defined fragments of APEX protein.

As discussed below, peptide fragments of APEX are particularly useful in: generating  
10 domain specific antibodies; identifying agents that bind to APEX or an APEX domain; identifying cellular factors that bind to APEX or an APEX domain; and isolating homologues or other allelic forms of APEX. APEX peptides, including particularly interesting structures, can be predicted and/or identified using various analytical techniques well known in the art (Rost, B., and Sander, C. 1994 *Proteins* 19:55-72), including, for  
15 example, the methods of Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis, or on the basis of immunogenicity. Fragments including such residues are particularly useful in generating subunit-specific anti-APEX antibodies or in identifying cellular factors that bind to APEX.

20 The APEX proteins of the invention may be useful for a variety of purposes, including but not limited to their use as diagnostic and/or prognostic markers on APCs or APEX-expressing cells, the ability to elicit the generation of antibodies, and as targets for various therapeutic modalities, as further described below. APEX proteins may also be used to identify and isolate ligands and other agents that bind to APEX.

25

## APEX ANTIBODIES AND USES THEREOF

### Antibodies

30 The invention further provides antibodies (e.g., polyclonal, monoclonal, chimeric, humanized, and human monoclonal antibodies) that bind to APEX. The most preferred

antibodies will selectively bind to APEX and will not bind (or will bind weakly) to non-APEX proteins. Anti-APEX antibodies that are particularly contemplated include monoclonal and polyclonal antibodies as well as fragments thereof (e.g., recombinant proteins) including the APEX antigen-binding domain and/or one or more complement  
5 determining regions of these antibodies. These antibodies can be from any source, e.g., rabbit, sheep, rat, dog, cat, pig, horse, mouse and human.

In one embodiment, the APEX antibodies specifically bind to the extracellular domain of an APEX protein. In other embodiments, the APEX antibodies specifically bind to other  
10 domains of an APEX protein or precursor, for example the APEX antibodies bind to the intracellular domain. As will be understood by those skilled in the art, the regions or epitopes of an APEX protein to which an antibody is directed may vary with the intended application. For example, antibodies intended for use in an immunoassay for the detection of membrane-bound APEX on viable cells should be directed to an accessible  
15 epitope on membrane-bound APEX. Antibodies that recognize other epitopes may be useful for the identification of APEX within damaged or dying cells, for the detection of secreted APEX proteins or fragments thereof.

The invention also encompasses antibody fragments that specifically recognize an APEX  
20 protein. As used herein, an antibody fragment is defined as at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen binding region. Some of the constant region of the immunoglobulin may be included.

For example, the predicted extracellular domain of APEX represents characteristics of a  
25 potential marker for screening, diagnosis, prognosis, and follow-up assays and imaging methods. In addition, these characteristics indicate that APEX may be an excellent target for therapeutic methods such as targeted antibody therapy, immunotherapy, and gene therapy to treat conditions associated with the presence or absence of APEX proteins.

30 Various methods for the preparation of antibodies are well known in the art. For example, antibodies may be prepared by immunizing a suitable mammalian host using an APEX

protein, peptide, or fragment, in isolated or immunoconjugated form (Harlow (1989), in: *Antibodies*, Cold Spring Harbor Press, NY). In addition, fusion proteins of APEX may also be used, such as an APEX-GST, or APEX-tagged fusion proteins, or APEX-human Ig- for example Human Ig and other mammalian species especially mouse. Cells expressing or  
5 overexpressing APEX may also be used for immunizations. Similarly, any cell engineered to express APEX may be used. This strategy may result in the production of monoclonal antibodies with enhanced capacities for recognizing endogenous APEX.

Chimeric antibodies of the invention are immunoglobulin molecules that comprise at  
10 least two antibody portions from different species, for example a human and non-human portion. The antigen combining region (variable region) of a chimeric antibody can be derived from a non-human source (e.g. murine), and the constant region of the chimeric antibody which confers biological effector function to the immunoglobulin, can be derived from a human source. The chimeric antibody should have the antigen binding  
15 specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule.

Antibodies of several distinct antigen binding specificities have been manipulated to produce chimeric proteins such as anti-TNP (Boulianne et al., *Nature* 312:643 (1984))  
20 and anti-tumor antigens (Sahagan et al., *J. Immunol.* 137:1066 (1986)). Likewise, several different effector functions have been achieved by linking new sequences to those encoding the antigen binding region. Some of these include enzymes (Neuberger et al., *Nature* 312:604 (1984)), immunoglobulin constant regions from another species and constant regions of another immunoglobulin chain (Sharon et al., *Nature* 309:364 (1984);  
25 Tan et al., *J. Immunol.* 135:3565-3567 (1985)). Additionally, procedures for modifying antibody molecules and for producing chimeric antibody molecules using homologous recombination to target gene modification have been described (Fell et al., *Proc. Natl. Acad. Sci. USA* 86:8507-8511 (1989)).

APEX mAbs can be used to stain the cell surface of APEX positive cells for detection. Additionally, some of the antibodies of the invention are internalizing antibodies, i.e., the antibodies are internalized into the cell upon or after binding.

- 5 The amino acid sequences of APEX proteins presented herein may be used to select specific regions of the APEX protein for generating antibodies. For example, hydrophobicity or hydrophilicity analyses of the APEX amino acid sequence may be used to identify hydrophilic regions in the APEX structure. Regions of the APEX protein that show immunogenic structure, as well as other regions and domains, can readily be identified using  
10 various other methods known in the art, such as Chou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis. Fragments including these residues are particularly suited for generating specific classes of anti-APEX antibodies.

- Methods for preparing a protein for use as an immunogen and for preparing immunogenic  
15 conjugates of a protein with a carrier such as BSA, KLH, or other carrier proteins are well known in the art (Harlow and Lane, 1988, in: *Antibodies: A Laboratory Manual*. Cold Spring Harbor Press). In some circumstances, direct conjugation using, for example, carbodiimide reagents may be employed; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, may be effective. Administration of an  
20 APEX immunogen is conducted generally by injection over a suitable time period and with use of a suitable adjuvant, as is generally understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of antibody formation.

- While the polyclonal antisera produced in this way may be satisfactory for some  
25 applications, for pharmaceutical compositions, monoclonal antibody preparations are preferred. Immortalized cell lines which secrete a desired monoclonal antibody may be prepared using the standard method of Kohler and Milstein (*Nature* 256: 495-497) or modifications which effect immortalization of lymphocytes or spleen cells, as are generally known. The immortalized cell lines secreting the desired antibodies are screened by  
30 immunoassay in which the antigen is the APEX protein or APEX fragment having APEX



activity. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro*, or by production in ascites fluid.

5 The desired monoclonal antibodies are then recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonal antibodies of the invention or the polyclonal antisera (e.g., Fab, F(ab')<sub>2</sub>, Fv fragments, fusion proteins), which include the immunologically significant portion (i.e., a portion that recognizes and binds APEX), can be used as antagonists, as well as the intact antibodies.

10 Humanized antibodies directed against APEX are also useful. As used herein, a humanized APEX antibody is an immunoglobulin molecule which is capable of binding to APEX, and which comprises a framework region (FR) region having substantially the amino acid sequence of a human immunoglobulin, and a complementarity determining region (CDR) having substantially the amino acid sequence of non-human immunoglobulin, or a sequence  
15 engineered to bind APEX. These humanized or "chimeric antibodies" are produced by splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity (Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81, 6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312, 604-608; and Takeda, S. et al. (1985) 314, 452-454). Alternatively, single chain antibodies may be  
20 developed using methods known in the art, to produce APEX-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may also be produced by chain shuffling from random combinatorial immunoglobulin libraries (Burton, D.R. (1991) *Proc. Natl. Acad. Sci.* 86, 3833-3837; Winter, G. et al. (1991) *Nature* 349, 293-299).

25

Use of immunologically reactive fragments, such as the Fab, Fab', or F(ab')<sub>2</sub> fragments is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin. The invention also provides pharmaceutical compositions having the monoclonal antibodies or anti-idiotypic monoclonal antibodies of  
30 the invention.

The antibodies or fragments may also be produced, using current technology, by recombinant means. Regions that bind specifically to the desired regions of the APEX protein can also be produced in the context of chimeric or CDR grafted antibodies of multiple species origin. The invention includes a monoclonal antibody, the antigen-  
5 binding region of which competitively inhibits the immunospecific binding of any of the monoclonal antibodies of the invention to its target antigen. Further, the invention provides recombinant proteins comprising the antigen-binding region of any the monoclonal antibodies of the invention.

- 10 Novel antibodies of human origin can be also made to the antigen having the appropriate biological functions. The completely human antibodies are particularly desirable for therapeutic treatment of human patients. The human monoclonal antibodies may be made by using the antigen, e.g. an APEX protein or peptide thereof, to sensitize human lymphocytes to the antigen *in vitro*, followed by EBV-transformation or hybridization of the antigen-  
15 sensitized lymphocytes with mouse or human lymphocytes, as described by Borrebaeck et al. (*Proc. Natl. Acad. Sci. USA* 85:3995-99 (1988)).

Alternatively, human antibodies can be produced using transgenic animals such as mice which are incapable of expressing endogenous immunoglobulin heavy and light chain  
20 genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of invention. Monoclonal antibodies directed against the antigen can be produced using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and  
25 subsequently undergo class switching and somatic mutations. Thus, using this technology, it is possible to produce therapeutically useful IgG, IgA, and IgB antibodies. For an overview of this technology to produce human antibodies, see Lonberg and Haszar (1995, *Int. Rev. Immunol.* 13:65-93). A detailed discussion of this technology for producing human antibodies and human monoclonal antibodies can be found in U.S. Patents 5,625,126;  
30 5,633,425; 5,569,825; 5,661,016; and 5,545,806.

The antibody, or fragment thereof, of the invention may be labeled with a detectable marker or conjugated to a second molecule, such as a therapeutic agent (e.g., a cytotoxic agent), thereby resulting in an immunoconjugate. For example, the therapeutic agent includes, but is not limited to, an anti-tumor drug, a toxin, a radioactive agent, a cytokine, a second antibody or an enzyme. Further, the invention provides an embodiment wherein the antibody of the invention is linked to an enzyme that converts a prodrug into a cytotoxic drug. The immunoconjugate can be used for targeting the second molecule to an APEX positive cell (Vitetta, E.S. et al., 1993 "Immunotoxin Therapy", in DeVita, Jr., V.T. et al., eds, *Cancer: Principles and Practice of Oncology*, 4th ed., J.B. Lippincott Co., Philadelphia, 2624-2636).

Examples of cytotoxic agents include, but are not limited to ricin, doxorubicin, daunorubicin, taxol, ethidum bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphtheria toxin, *Pseudomonas* exotoxin (PE) A, PE40, abrin, and glucocorticoid and other chemotherapeutic agents, as well as radioisotopes. Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme.

Additionally, the recombinant protein of the invention comprising the antigen-binding region of any of the monoclonal antibodies of the invention, can be used to treat diseases associated with the presence of APEX proteins. In such a situation, the antigen-binding region of the recombinant protein is joined to at least a functionally active portion of a second protein having therapeutic activity. The second protein can include, but is not limited to, an enzyme, lymphokine, oncostatin or toxin. Suitable toxins include doxorubicin, daunorubicin, taxol, ethidum bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphtheria toxin, *Pseudomonas* exotoxin (PE) A, PE40, ricin, abrin, glucocorticoid and radioisotopes.

Techniques for conjugating or joining therapeutic agents to antibodies are well known (see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.*, 62:119-58 (1982)).

10

### Use of the Antibodies

APEX antibodies of the invention may be particularly useful in diagnostic assays and imaging methodologies. The invention provides various immunological assays useful for the detection of APEX proteins. Such assays generally comprise one or more APEX antibodies capable of recognizing and binding an APEX protein, and include various immunological assay formats well known in the art, including but not limited to various types of precipitation, agglutination, complement fixation, radioimmunoassays (RIA), enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA) (H. Liu et al. *Cancer Research* 58: 4055-4060 (1998), immunohistochemical analysis and the like.

In order to provide a basis for diagnosis, normal or standard values for APEX expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects with antibody to APEX under conditions suitable for complex formation, which are well known in the art. The amount of standard complex formation may be quantified by comparing various artificial membranes containing known quantities of APEX with both control and disease samples from biopsied tissues. Then, standard values obtained from normal samples may be compared with values obtained from subjects potentially affected by disease. Deviation between standard and subject values establishes the presence of a disease state.

In addition, immunological imaging methods capable of detecting APEX-expressing cells are also provided by the invention, including, but not limited to, radioscintigraphic imaging methods using labeled APEX antibodies. Such assays may be clinically useful in the  
5 detection and monitoring.

In one embodiment, APEX antibodies and fragments thereof (e.g., Fv, Fab', F(ab')<sub>2</sub>) are used for detecting the presence of a cell expressing an APEX protein. The presence of such APEX positive (+) cells within various biological samples, including blood, serum,  
10 urine, tissue, etc., may be detected with APEX antibodies. In addition, APEX antibodies may be used in various imaging methodologies, such as immunoscintigraphy with Indium-111 (or other isotope) conjugated antibody (Sodee et al., 1997, Clin Nuc Med 21: 759-766). APEX antibodies may also be used therapeutically to inhibit APEX function.

15 APEX antibodies may be used in methods for purifying APEX proteins and peptides and for isolating APEX homologues and related molecules. For example, in one embodiment, the method of purifying APEX protein comprises incubating an APEX antibody, which has been coupled to a solid matrix, with a lysate or other solution including APEX under conditions which permit the APEX antibody to bind to APEX; washing the solid matrix to  
20 eliminate impurities; and eluting the APEX from the coupled antibody. Additionally, APEX antibodies may be used to isolate APEX positive cells using cell sorting and purification techniques. The presence of APEX on cells (alone or in combination with other cell surface markers) may be used to distinguish and isolate APEX-expressing cells from other cells, using antibody-based cell sorting or affinity purification techniques. Other  
25 uses of the APEX antibodies of the invention include generating anti-idiotypic antibodies that mimic the APEX protein, e.g., a monoclonal anti-idiotypic antibody reactive with an idioype on any of the monoclonal antibodies of the invention.

The antibodies of the invention may be used to generate large quantities of relatively pure  
30 APEX-positive cells which can be grown in tissue culture or administered *ex vivo* to a subject.

Another valuable application of using antibodies to generate APEX-positive cells is the ability to isolate, analyze and experiment with relatively pure preparations of viable APEX positive cells cloned from individual subjects or patients. In this way, for example, an individual subject's cells may be expanded from a limited biopsy sample and then tested for the presence of diagnostic and prognostic genes, proteins, chromosomal aberrations, gene expression profiles, or other relevant genotypic and phenotypic characteristics, without the potentially confounding variable of contaminating cells. Similarly, patient-specific vaccines and cellular immunotherapeutics may be created from such cell preparations.

Other uses of the APEX antibodies of the invention include generating anti-idiotypic antibodies that mimic the APEX proteins of the invention, e.g., a monoclonal anti-idiotypic antibody reactive with an idiotype on any of the monoclonal antibodies of the invention. Anti-idiotypic antibodies of the APEX antibody may be used therapeutically in the treatment of APEX-associated disorders.

## **METHODS FOR ISOLATING ADDITIONAL APEX-ENCODING NUCLEIC ACID MOLECULES**

The APEX-encoding nucleic acid molecules described herein enable the isolation of APEX homologues, alternatively sliced isoforms, allelic variants, and mutant forms of the APEX protein as well as their coding and gene sequences. The most preferred sources of APEX homologues are mammalian organisms.

For example, a portion of the APEX-encoding sequence herein described can be synthesized and used as a probe to retrieve DNA encoding a member of the APEX family of proteins from organisms other than human, allelic variants of the human APEX protein herein described, and genomic sequence including the *apex* gene. Oligomers containing approximately 18-20 nucleotides (encoding about a 6-7 amino acid stretch) are prepared and used to screen genomic DNA or cDNA libraries to obtain hybridization under stringent

conditions, or conditions of sufficient stringency, to eliminate an undue level of false positives.

5 In addition, the amino acid sequence of the human or murine APEX protein may be used to generate antibody probes to screen expression libraries prepared from cells to obtain APEX homologues from other mammalian species. Typically, polyclonal antiserum from mammals such as rabbits immunized with the purified protein or monoclonal antibodies can be used to probe an expression library prepared from a target organism, to obtain the appropriate coding sequence for an APEX homologue. The cloned cDNA sequence can be  
10 expressed as a fusion protein, expressed directly using its own control sequences, or expressed by constructing an expression cassette using control sequences appropriate to the particular host used for expression of the enzyme.

15 Genomic clones including APEX genes may be obtained using molecular cloning methods well known in the art. In one embodiment, an *apex* cDNA probe can be used to screen a genomic library, such as libraries constructed in lambda phage, or BAC (bacterial artificial chromosome) or YAC (yeast artificial chromosome), to obtain a genomic clone of an *apex* gene.

20 Additionally, pairs of oligonucleotide primers can be prepared for use in a polymerase chain reaction (PCR) to selectively amplify/clone an APEX-encoding nucleic acid molecule, or fragment thereof. A PCR denature/anneal/extend cycle for using such PCR primers is well known in the art (U. S. Patent No. 4,683,202 and 4,965,188) and can readily be adapted for use in isolating other APEX-encoding nucleic acid molecules.

25 Non-human homologues of *apex*, naturally occurring allelic variants of *apex* and genomic *apex* sequences will share a high degree of homology to the human *apex* sequences herein described. In general, such nucleic acid molecules will hybridize to the human *apex* sequence under stringent conditions. Such sequences will typically have at least 70%  
30 homology, preferably at least 80%, and most preferably at least 90% homology to the human *apex* sequence.

Stringent conditions are those that employ low ionic strength and high temperature for washing. For example, stringent salt concentration will ordinarily be less than 750 mM NaCl and 75 mM sodium citrate, preferably less than about 500 mM NaCl and 50 mM sodium citrate, and most preferably less than about 250 mM NaCl and 25 mM sodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will normally include a temperature of at least about 30°C, more preferably at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA are well known to those skilled in the art. Various levels of stringency are achieved by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM sodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM sodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM sodium citrate, 1% SDS, 50% formamide, and 200 µg/ml ssDNA. Appropriate variations on these conditions will be readily apparent to those skilled in the art.

The washing steps that follow hybridization can also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As with the hybridization, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM sodium citrate, and most preferably, less than about 15 mM NaCl and 1.5 mM sodium citrate. Stringent temperature conditions for wash steps will normally include a temperature of at least 25°C, more preferably of at least 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM sodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in



15 mM NaCl, 1.5 mM sodium citrate and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM sodium citrate, and 0.1% SDS. A skilled artisan can readily determine and vary the stringency conditions appropriately to obtain a clear and detectable hybridization signal.

5

## RECOMBINANT DNA MOLECULES HAVING APEX-ENCODING NUCLEIC ACID MOLECULES

Also provided are recombinant DNA molecules (rDNAs) that include APEX-encoding sequences as herein described, or fragments thereof. As used herein, a rDNA molecule is a DNA molecule that has been subjected to molecular manipulation *in vitro*. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook *et al.*, *Molecular Cloning* (1989). In the preferred rDNA molecules of the present invention, an APEX-encoding DNA sequence that encodes an APEX protein or a fragment of APEX, is operably linked to one or more expression control sequences and/or vector sequences. The rDNA molecule can encode either the entire APEX protein, or can encode a fragment of the APEX protein having APEX activity.

The choice of vector and/or expression control sequences to which the APEX-encoding sequence is operably linked depends directly, as is well known in the art, on the functional properties desired, e.g., protein expression, and the host cell to be transformed. A vector contemplated by the present invention is at least capable of directing the replication or insertion into the host chromosome, and preferably also expression, of the APEX-encoding sequence included in the rDNA molecule.

25

Expression control elements that are used for regulating the expression of an operably linked protein encoding sequence are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, enhancers, transcription terminators and other regulatory elements. Preferably, an inducible promoter that is readily controlled, such as being responsive to a nutrient in the host cell's medium, is used.

30

- In one embodiment, the vector comprising an APEX-encoding nucleic acid molecule will include a prokaryotic replicon, i.e., a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule intrachromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith. Such replicons are well known in the art. In addition, vectors that include a prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a drug resistance. Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.
- 10 Vectors that include a prokaryotic replicon can further include a prokaryotic or viral promoter capable of directing the expression (transcription and translation) of the APEX-encoding sequence in a bacterial host cell, such as *E. coli*. A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with bacterial hosts are typically
- 15 provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention. Various viral vectors well known to those skilled in the art may also be used, such as, for example, a number of well-known retroviral and adenoviral vectors.
- 20 Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can also be used to express rDNA molecules that include an APEX-encoding sequence. Eukaryotic cell expression vectors are well known in the art and are available from several commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired DNA segment. Typical of such
- 25 vectors are PSVL and pKSV-10 (Pharmacia, Uppsala, Sweden), pBPV-1/pML2d (International Biotechnologies, Inc.), pTDT1 (ATCC, #31255), and similar eukaryotic expression vectors.

Eukaryotic cell expression vectors used to construct the rDNA molecules of the present invention may further include a selectable marker that is effective in an eukaryotic cell, preferably a drug resistance selection marker. A preferred drug resistance marker is the

30

gene whose expression results in neomycin resistance, i.e., the neomycin phosphotransferase (*neo*) gene. Alternatively, the selectable marker can be present on a separate plasmid, and the two vectors are introduced by co-transfection of the host cell, and selected by culturing in the presence of the appropriate drug for the selectable marker.

5

In accordance with the practice of the invention, the vector can be a plasmid, cosmid or phage vector encoding the cDNA molecule discussed above. Additionally, the invention provides a host-vector system comprising the plasmid, cosmid or phage vector transfected into a suitable eukaryotic host cell. Examples of suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell. The host-vector system is useful for the production of an APEX protein. Alternatively, the host cell can be prokaryotic, such as a bacterial cell.

10

#### RECOMBINANT METHODS OF GENERATING APEX PROTEINS

15

The invention further provides methods for producing an APEX protein using APEX-encoding nucleic acid molecules herein described. In general terms, the production of a recombinant APEX protein typically involves the following steps:

20 First, a nucleic acid molecule is obtained that encodes an APEX protein or a fragment thereof, such as the nucleic acid molecule depicted in Figures 5, 6, or 7. The APEX-encoding nucleic acid molecule is then preferably placed in an operable linkage with suitable expression control sequences, as described above, to generate an expression unit comprising the APEX-encoding sequence. The expression unit is used to transform a  
25 suitable host and the transformed host is cultured under conditions that allow the production of the APEX protein. The APEX protein is isolated from the medium or from the cells; recovery and purification of the protein may not be necessary in some instances where some impurities may be tolerated.

30 Each of the foregoing steps may be done in a variety of ways. For example, the desired coding sequences may be obtained from genomic fragments and used directly in an

- appropriate host. The construction of expression vectors that are operable in a variety of hosts is accomplished using an appropriate combination of replicons and control sequences. The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene and were discussed in detail earlier. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors. A skilled artisan can readily adapt any host/expression system known in the art for use with APEX-encoding sequences to produce an APEX protein.
- 10 In order to express a biologically active APEX, the nucleotide sequence encoding *apex* or its functional equivalent, is inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.
- 15 Methods which are well known to those skilled in the art can be used to construct expression vectors comprising an *apex* coding sequence and appropriate transcriptional or translational controls. These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination or genetic recombination. Such techniques are described in Sambrook et al (1989) in: *Molecular Cloning, A Laboratory*
- 20 *Manual*, Cold Spring Harbor Press, Plainview N.Y. and Ausubel F M et al. (1989) in: *Current Protocols in Molecular Biology*, John Wiley & Sons, New York N.Y.

- A variety of expression vector/host systems may be utilized to contain and express an *apex* coding sequence. These include but are not limited to microorganisms such as
- 25 bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transfected with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV), or transformed with bacterial expression vectors (e.g., Ti or pBR322
- 30 plasmid), or animal cell systems.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be obtained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes (Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355).

The "control elements" or "regulatory sequences" of these systems vary in their strength and specificities and are those nontranslated regions of the vector, enhancers, promoters, and 3' untranslated regions, which interact with host cellular proteins to carry out transcription and translation. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla Calif.) or PSPORTI (Gibco BRL) and ptrp-lac hybrids, and the like, may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from the mammalian genes or from mammalian viruses are appropriate. If it is necessary to generate a cell line that includes multiple copies of *apex*, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

The invention also provides chimeric or fusion proteins. As used herein, a "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of a polypeptide of the invention operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same polypeptide of the invention). Within the fusion protein, the term "operably linked" is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of the polypeptide of the invention.

Heterologous protein and peptide moieties may facilitate purification of fusion protein using commercially available affinity matrices. In addition, a chimeric APEX protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of APEX activity. Such

5 heterologous moieties include, but are not limited to glutathione-S-transferase (GST), immunoglobulin (Ig), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding protein (CBP), 6-His, FLAG, and hemagglutinin (HA). A fusion protein may be engineered to contain a proteolytic cleavage site located between the APEX encoding sequences and the heterologous protein sequence, so that the APEX sequences may be

10 cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion protein.

15 In one embodiment, the fusion protein is a GST-fusion protein in which the polypeptides of the invention are fused to the C-terminus of GST sequences. In a more preferred embodiment, the fusion protein is an immunoglobulin fusion protein in which all or parts of a polypeptide of the invention is fused to sequence derived from a member of the immunoglobulin protein family. The fusion proteins of the invention can facilitate the

20 purification of recombinant polypeptides of the invention. The immunoglobulin fusion proteins of the invention can also increase the solubility of the polypeptides of the invention. The immunoglobulin fusion protein of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane bound) and a protein on the surfaces of cells (receptor), to

25 thereby suppress signal transduction *in vivo*. Inhibition of ligand-receptor interactions may be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (e.g. promoting or inhibiting) cell survival. The immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against polypeptides of the invention in a subject, to purify ligands and in screening assays to identify

30 molecules which inhibit the interaction of receptors with ligands.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for the APEX proteins. For example, when large quantities of APEX proteins are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified, may be desirable. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the APEX coding sequence may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke & Schuster (1989) *J Biol Chem* 264:5503-5509); and the like. pGEX vectors (Promega, Madison Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads, followed by elution in the presence of free glutathione. Proteins made in such systems are designed to include heparin, thrombin or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as  $\beta$ - factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel et al (*supra*) and Grant et al (1987) *Methods in Enzymology* 153:516-544.

In cases where plant expression vectors are used, the expression of a sequence encoding an APEX protein may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV (Brisson et al (1984) *Nature* 310:511-514) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu et al (1987) *EMBO J* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi et al (1984) *EMBO J* 3:1671-1680; Broglie et al (1984) *Science* 224:838-843); or heat shock promoters (Winter J and Sinibaldi R M (1991) *Results Probl Cell Differ* 17:85-105) may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobb, S. or Murry, L E in: *McGraw*

*Yearbook of Science and Technology* (1992) McGraw Hill New York N.Y., pp 191-196, or Weissbach and Weissbach (1988) *Methods for Plant Molecular Biology*, Academic Press, New York N.Y., pp 421-463.

- 5 An alternative expression system which could be used to express APEX proteins is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The APEX coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the
- 10 polyhedrin promoter. Successful insertion of APEX will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses are then used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which APEX protein is expressed (Smith et al (1983) *J Virol* 46:584; Engelhard E K et al (1994) *Proc Nat Acad Sci* 91:3224-7).
- 15
- In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, an *apex* coding sequence may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the
- 20 viral genome will result in a viable virus capable of expressing APEX in infected host cells. (Logan and Shenk (1984) *Proc Natl Acad Sci* 81:3655-59). In addition, transcription enhancers, such as the rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.
- 25
- Specific initiation signals may also be required for efficient translation of an *apex* sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where the *apex* initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted,
- 30 exogenous transcriptional control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure



transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf, D. et al (1994) *Results Probl Cell Differ* 20:125-62; Bittner et al (1987) *Methods in Enzymol* 153:516-544).

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express APEX may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase genes (Lowy I et al (1980) *Cell* 22:817-23) which can be employed in tk-negative or aprt-negative cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al (1980) *Proc Natl Acad Sci* 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) *J Mol Biol* 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) *Proc Natl Acad Sci* 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins,  $\beta$ -glucuronidase and its substrate, GUS, and luciferase and its substrate, luciferin, being widely used not only to

identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et al (1995) *Methods Mol Biol* 55:121-131).

- 5 Host cells transformed with nucleotide sequences encoding APEX proteins may be cultured under conditions suitable for the expression and recovery of the APEX protein from cell culture. The APEX protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequences and/or the vector used. As will be understood by those skilled in the art, expression vectors containing polynucleotides  
10 which encode APEX proteins may be designed to contain signal sequences which direct secretion of APEX proteins through a prokaryotic or eukaryotic cell membrane.

- In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted *apex* sequences or to process the expressed APEX protein in the desired fashion.  
15 Such modifications of the APEX polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a 'prepro' form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e. g., COS,  
20 CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Tissue Collection (ATCC, Bethesda, MD), and may be chosen to ensure the correct modification and processing of the foreign APEX protein.

## 25 ASSAYS FOR IDENTIFYING APEX LIGANDS AND OTHER BINDING AGENTS

- Another aspect of the invention relates to assays and methods that can be used to detect and identify APEX ligands and other agents and cellular constituents that bind to APEX. Specifically, APEX ligands and other agents and cellular constituents that bind to APEX can be identified by the ability of the APEX ligand or other agent or constituent to bind to  
30 APEX and/or the ability to inhibit/stimulate APEX activity. Assays for APEX activity (e.g., binding) using an APEX protein are suitable for use in high throughput screening methods.

In one embodiment, the assay comprises mixing APEX with a test agent or cellular extract. After mixing under conditions that allow association of APEX with the agent or component of the extract, the mixture is analyzed to determine if the agent/component is bound to APEX. Binding agents/components are identified as being able to bind to APEX. Alternatively or consecutively, APEX activity can be directly assessed as a means for identifying agonists and antagonists of APEX activity.

Alternatively, targets that bind to an APEX protein can be identified using a yeast two-hybrid system (Fields, S. and Song, O. (1989) *Nature* 340:245-246), or using a binding-capture assay (Harlow, *supra*). Generally, the yeast two-hybrid system is performed in a yeast host cell carrying a reporter gene, and is based on the modular nature of the GAL transcription factor which has a DNA binding domain and a transcriptional activation domain. The two-hybrid system relies on the physical interaction between a recombinant polypeptide that comprises the DNA binding domain and another recombinant polypeptide that comprises the transcriptional activation domain, to reconstitute the transcriptional activity of the modular transcription factor, thereby causing expression of the reporter gene. Either of the recombinant polypeptides used in the two-hybrid system can be constructed to include the APEX-encoding sequence to screen for cellular binding partners of APEX protein. The yeast two-hybrid system can be used to screen cDNA expression libraries (G. J. Hannon, et al. (1993) *Genes and Dev.* 7: 2378-2391), and random aptamer libraries (J. P. Manfredi, et al. (1996) *Molec. And Cell. Biol.* 16: 4700-4709), or semi-random (M. Yang, et al. (1995) *Nucleic Acids Res.* 23: 1152-1156) aptamers libraries for APEX ligands.

APEX proteins which may be used in the above assays include, but are not limited to, an isolated APEX protein, a fragment of an APEX protein having APEX activity, a cell that has been altered to express an APEX protein, or a fraction of a cell that has been altered to express an APEX protein. Further, the APEX protein can be the entire APEX protein or a defined fragment of the APEX protein having APEX activity. It will be apparent to one of ordinary skill in the art that so long as the APEX protein can be assayed for agent binding,

e.g., by a shift in molecular weight or activity, or the expression of a reporter gene in a two-hybrid system.

5 The method used to identify whether an agent/cellular component binds to an APEX protein will be based primarily on the nature of the APEX protein used. For example, a gel retardation assay can be used to determine whether an agent binds to APEX or a fragment thereof. Alternatively, immunodetection and biochip (e.g., U.S. Patent No. 4,777,019) technologies can be adopted for use with the APEX protein. A skilled artisan can readily employ numerous art-known techniques for determining whether a particular agent binds to  
10 an APEX protein.

Agents and cellular components can be further tested for the ability to modulate the activity of an APEX protein using a cell-free assay system or a cellular assay system. As the activities of the APEX protein become more defined, functional assays based on the  
15 identified activity can be employed.

Agents that bind an APEX protein, such as an APEX antibody, can be used to modulate the activity of APEX, to target anticancer agents to appropriate mammalian cells, or to identify agents that block the interaction with APEX. Cells expressing APEX can be targeted or  
20 identified by using an agent that binds to APEX.

How the APEX binding agents will be used depends on the nature of the APEX binding agent. For example, an APEX binding agent can be used to deliver conjugated toxins, such a diphtheria toxin, cholera toxin, ricin or pseudomonas exotoxin, to an APEX expressing  
25 cell; modulate APEX activity; to directly kill APEX expressing cells, or in screens to identify competitive binding agents. For example, an APEX inhibitory agent can be used to directly inhibit the growth of APEX expressing cells, whereas an APEX binding agent can be used as a diagnostic agent.

30 As used herein, an agent is said to antagonize APEX activity when the agent reduces APEX activity. The preferred antagonist will selectively antagonize APEX, not affecting any other

cellular proteins. Further, the preferred antagonist will reduce APEX activity by more than 50%, more preferably by more than 90%, most preferably eliminating all APEX activity.

As used herein, an agent is said to agonize APEX activity when the agent increases APEX activity. The preferred agonist will selectively agonize APEX, not affecting any other cellular proteins. Further, the preferred antagonist will increase APEX activity by more than 50%, more preferably by more than 90%, most preferably, more than doubling APEX activity.

Agents that are assayed in the above method can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences of the APEX protein. An example of randomly selected agents is the use of a chemical library or a peptide combinatorial library, or a growth broth of an organism or plant extract.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a nonrandom basis that takes into account the sequence of the target site and/or its conformation in connection with the agent's action. Agents can be rationally selected or rationally designed by utilizing the peptide sequences that make up the APEX protein. For example, a rationally selected peptide agent can be a peptide whose amino acid sequence is identical to a fragment of an APEX protein having APEX activity.

The agents can be, as examples, peptides, small molecules, and vitamin derivatives, as well as carbohydrates. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents used in the present screening method. One class of agents of the present invention is peptide agents whose amino acid sequences are chosen based on the amino acid sequence of the APEX protein. Small peptide agents can serve as competitive inhibitors of APEX protein assembly.

Peptide agents can be prepared using standard solid phase (or solution phase) peptide synthesis methods, as is known in the art. In addition, the DNA encoding these peptides

may be synthesized using commercially available oligonucleotide synthesis instrumentation and produced recombinantly using standard recombinant production systems. The production using solid phase peptide synthesis is necessitated if non-gene-encoded amino acids are to be included.

5

Another class of agents of the present invention are antibodies immunoreactive with selected domains or regions of the APEX protein. As described above, antibodies are obtained by immunization of suitable mammalian subjects with peptides, comprising as antigenic regions, those portions of the APEX protein intended to be targeted by the antibodies. Regions of particular interest may include the extracellular domain of an APEX polypeptide. Such agents can be used in competitive binding studies to identify second generation inhibitory agents.

The cellular extracts tested in the methods of the present invention can be, as examples, aqueous extracts of cells or tissues, organic extracts of cells or tissues or partially purified cellular fractions. A skilled artisan can readily recognize that there is no limit as to the source of the cellular extract used in the screening method of the present invention.

## USES OF THE INVENTION

20

There are multiple uses of the invention. For example, the nucleic acid molecules of the invention and their encoded proteins (also referred to herein as APEX proteins or protein of the invention), may be employed as molecular weight markers. The molecular weight of each of the gene sequences and proteins can be determined and once determined can be used to compare against other gene sequences and proteins whose molecular weights are unknown. For example, the nucleotide length of *apex-1* is 2704 as described in SEQ ID NO. 1; *apex-2* is 1516 as described in SEQ ID NO. 2; *apex-3* is 1408 as described in SEQ ID NO. 3.

### Detection and Mapping of Related Polynucleotide sequences

- The nucleic acid molecules of the invention can be used to map the location of their corresponding genes and other related naturally occurring genomic sequences. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome, and, thus, locate gene regions associated with disease. There are several approaches for chromosome mapping. For example, chromosome mapping can be accomplished by PCR mapping of somatic cell hybrids (D'Eustachio et al. (1983) *Science* 220:919-924). Other approaches for chromosome mapping include but are not limited to *in situ* hybridization (Fan et al. (1990) *Proc. Natl. Acad. Sci. USA* 87: 6223-27), fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread (Verma et al., Human Chromosome: A manual of Basic Techniques, Pergamon press, New York, 1988).
- In situ* hybridization of chromosomal preparation and physical mapping techniques such as linkage analysis using established chromosomal markers can be used to extend genetic maps. Once a disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, any sequences mapping to that region may represent associated or regulatory genes for further investigation. The nucleotide sequences of the invention may also be used to detect differences in the chromosome location due to translocation, inversion, etc. among normal, carrier or affected individuals.

### Functional Assays

- The molecules of the invention can be used to assess and elaborate functions of APEX proteins by expressing the sequences encoding APEX at physiologically elevated levels in mammalian cell culture systems. For example the cDNA encoding a particular APEX protein is subcloned into a mammalian expression vector containing a strong promoter such as CMV immediate-early promoter, that drives high level of cDNA expression. The recombinant vector containing the *apex* sequences is cotransfected along with an additional plasmid containing sequences encoding a marker protein, such as Green

Fluorescent Protein, into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulation, calcium precipitation, or electroporation. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Flow cytometry (FCM) is used to identify transfected cells expressing the marker protein, and to evaluate properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA contents as measured by DNA staining, changes in cell size and granularity, down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake, alteration in expression of cell surface and intracellular proteins as measured by reactivity with specific monoclonal antibodies, and alteration in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface.

#### 15 Diagnostic Uses of the Invention

There are multiple diagnostic uses of the invention. For example, the invention provides methods for diagnosing in a subject, e.g., an animal or human subject, a disease associated with the presence or absence of the APEX protein. In one embodiment, the method comprises quantitatively determining the amount of APEX protein in the sample (e.g., cell or biological fluid sample) using any one or combination of the antibodies of the invention. Then the amount so determined can be compared with the amount in a sample from a normal subject. The presence of a measurably different amount (i.e., the number of APEX proteins in the test sample exceeds or is reduced from the number of APEX proteins in a normal sample) in the samples, indicating the presence of the disease.

In another embodiment, diagnosis involves quantitatively determining in a sample from the subject the amount of RNA transcripts encoding the APEX protein using the nucleic acid molecules of the invention. The amount so determined can be compared with the amount of RNA in a sample from a normal subject. Once again, the presence of a



measurably different amount indicates the presence of a disease associated with the over- or under-abundance of APEX-encoding transcripts.

5 Additionally, the invention provides methods for monitoring the course of disease or disorders associated with APEX in a subject by measuring the amount of APEX in a sample from the subject at various points in time. This is done for purposes of determining a change in the amount of APEX in the sample e.g., to determine whether the change is a small change in the amount or a large change, i.e., overexpression of APEX. In one embodiment, the method comprises quantitatively determining in a first  
10 sample from the subject the presence of an APEX protein and comparing the amount so determined with the amount present in a second sample from the subject, such samples being taken at different points in time, a difference in the amounts determined being indicative of the course of the disease.

15 In another embodiment, monitoring is effected by quantitatively determining in a first sample from the subject the presence of an *apex* RNA transcript and comparing the amount so determined with the amount present in a second sample from the subject, such samples being taken at different points in time, a difference in the amounts determined being indicative of the course of the disease associated with *apex* expression.

20 As a further embodiment, the diseases or disorders associated with APEX can be monitored in a sample by detecting an increase in or increased APEX gene copy number. An increase in or increased APEX gene copy number is important because it may correlate with poor outcome.

25 The diagnostic sample can be from an animal or a human. Further, the sample can be a cell sample. For example, using the methods of the invention, spleen, lymph node, thymus, bone marrow, liver, heart, brain, placenta, lung, skeletal muscle, kidney and pancreas can be evaluated for the presence of disease. Alternatively, the sample can be a  
30 biological fluid, e.g., urine, blood sera or plasma.

In accordance with the practice of the invention, detection can be effected by immunologic detection means involving histology, blotting, ELISA, and ELIFA. When the sample is a tissue or cell sample it can be formalin-fixed, paraffin-embedded or frozen.

- 5 The invention additionally provides methods of determining a difference in the amount and distribution of APEX in tissue sections from a neoplastic tissue to be tested relative to the amount and distribution of APEX in tissue sections from a normal tissue. In one embodiment, the method comprises contacting both the tissue to be tested and the normal tissue with a monoclonal antibody that specifically forms a complex with APEX, and  
10 thereby detecting the difference in the amount and distribution of APEX.

Further, the invention provides a method for diagnosing a neoplastic or preneoplastic condition in a subject. This method comprises obtaining from the subject a sample of a tissue, detecting a difference in the amount and distribution of APEX in the using the  
15 method above, a distinct measurable difference being indicative of such neoplastic or preneoplastic condition.

In accordance with the practice of the invention, the antibody can be directed to the epitope to which any of the monoclonal antibodies of the invention is directed. Further, the tissue  
20 sample can be from, for example, the spleen, lymph node, thymus, bone marrow, liver, heart, brain, placenta, lung, skeletal muscle, kidney, pancreas.

The invention also provides methods of detecting and quantitatively determining the concentration of APEX in a biological fluid sample. In one embodiment the method  
25 comprises contacting a solid support with an excess of one or more monoclonal antibodies which forms (preferably, specifically forms) a complex with APEX under conditions permitting the monoclonal antibody to attach to the surface of the solid support. The resulting solid support to which the monoclonal antibody is attached is then contacted with a biological fluid sample so that the APEX in the biological fluid binds to  
30 the antibody and forms an APEX-antibody complex. The complex can be labeled directly or indirectly with a detectable marker. Alternatively, either the APEX or the

antibody can be labeled before the formation of the complex. The complex can then be detected and quantitatively determined thereby detecting and quantitatively determining the concentration of APEX in the biological fluid sample. A high or low concentration of APEX in the sample relative to normal cells indicates a neoplastic or preneoplastic condition.

In accordance with the practice of the invention, the biological fluid includes, but is not limited to tissue extract, urine, blood, serum, and phlegm. Further, the detectable marker includes but is not limited to an enzyme, biotin, a fluorophore, a chromophore, a heavy metal, a paramagnetic isotope, or a radioisotope.

Further, the invention provides a diagnostic kit comprising an antibody that recognizes and binds APEX (an anti-APEX antibody); and a conjugate of a detectable label and a specific binding partner of the anti-APEX antibody. In accordance with the practice of the invention the label includes, but is not limited to, enzymes, radiolabels, chromophores and fluorescers.

Methods to extend the DNA sequence from an oligonucleotide primer annealed to the DNA template of interest have been developed for both single-stranded and double-stranded templates. Chain termination reaction products are separated using electrophoresis and detected via their incorporated, labeled precursors. Recent improvements in mechanized reaction preparation, sequencing and analysis have permitted expansion in the number of sequences that can be determined per day. Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno Nev.), Peltier Thermal Cycler (PTC200; MJ Research, Watertown Mass.) and the ABI 377 DNA sequencers (Perkin Elmer).

The nucleotide sequence of APEX may be extended utilizing partial nucleotide sequence, and various methods known in the art, to detect upstream sequences such as promoters and regulatory elements. Useful nucleotide sequences may be joined to APEX in an assortment of cloning vectors, e.g., plasmids, cosmids, lambda phage derivatives,

phagemids, and the like, that are well known in the art. In general, these vectors will contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for the host cell.

- 5 The nucleic acid molecules of the invention and their encoded proteins, may be employed in diagnostic embodiments. For example, the amount of such sequences present within a biological sample, such as blood, serum or a swab from nose, ear or throat, may be determined by means of a molecular biological assay to determine the level of nucleic acid complementary to the gene sequence of the invention, or even by means of an  
10 immunoassay to determine the level of one of the products encoded by the gene.

- In a molecular biological method for detecting the nucleotide sequences of the invention, one would obtain nucleic acid molecules from a suitable sample and analyze the nucleic acid molecules, using a nucleic acid probe, to identify a specific nucleotide sequence that  
15 is complementary to the probe. The complementary nucleic acid molecule will generally be identified by sequence, which method generally includes either; identifying a transcript with a corresponding or complementary sequence, e.g., by Northern or Southern blotting using an appropriate probe or; by identifying a transcript with two or more shorter primers and amplifying with PCR technology.

- 20 To conduct such a diagnostic method, one would generally obtain nucleic acid molecules from the sample and contact the nucleic acid molecules with a nucleic acid probe corresponding thereto, under conditions effective to allow hybridization of substantially complementary nucleotide sequences, and then detect the presence of any hybridized  
25 substantially complementary nucleic acid complexes that formed.

- The presence of a substantially complementary nucleotide sequence in a sample, or a significantly increased level of such a sequence, in comparison to the levels in a normal or "control" sample, will thus be indicative of a sample having the nucleotide sequence of  
30 the invention. Here, substantially complementary nucleotide sequences are those that

have relatively little sequence divergence and that are capable of hybridizing to the sequences disclosed herein under standard high stringency conditions.

5 As used herein, the term "increased levels" is used to describe a significant increase in the amount of the gene sequence of the invention detected in a given sample in comparison to that observed in a control sample, e.g., an equivalent sample from a normal healthy subject.

10 A variety of hybridization techniques and systems are known that can be used in connection with the detection aspects of the invention, including diagnostic assays such as those described in Falkow et al., U.S. Pat. No. 4,358,535.

15 In general, the "detection" of the nucleotide sequence of the invention is accomplished by attaching or incorporating a detectable label into the nucleic acid molecule used as a probe and "contacting" a sample nucleic acid molecule with the labeled probe. In such processes, an effective amount of the labeled probe is brought into direct juxtaposition with a composition containing the target nucleotide sequence. Hybridized nucleic acid complexes may then be identified by detecting the presence of the label, for example, by detecting a radio, enzymatic, fluorescent, or even chemiluminescent label.

20 Many suitable variations of hybridization technology are available for use in the detection of target nucleotide sequences, as will be known to those of skill in the art. These include, for example, *in situ* hybridization, Southern blotting and Northern blotting. *In situ* hybridization describes the techniques wherein the target nucleotide sequences contacted with the probe sequences are those located within one or more cells, such as cells within  
25 a clinical sample or even cells grown in tissue culture. As is well known in the art, the cells are prepared for hybridization by fixation, e.g. chemical fixation, and placed in conditions that allow for the hybridization of a detectable probe with nucleotide sequences located within the fixed cell.

30

Alternatively, target nucleic acid molecules may be separated from a cell or sample prior to contact with a probe. Any of the wide variety of methods for isolating target nucleic acid molecules may be employed, such as cesium chloride gradient centrifugation, chromatography (e.g., ion, affinity, magnetic), phenol extraction and the like. Most often,  
5 the isolated nucleic acid molecules will be separated, e.g., by size, using electrophoretic separation, followed by immobilization onto a solid matrix, prior to contact with the labeled probe. These prior separation techniques are frequently employed in the art and are generally encompassed by the terms "Southern blotting" and "Northern blotting".

10 It is possible to detect the nucleic acid molecules of the invention using a method based upon PCR technology. To conduct such a diagnostic method, one would generally obtain sample nucleic acid molecules from a suitable source and contact the sample nucleic acid molecules with two probes or primers corresponding to the *apex* nucleotide sequence disclosed herein, under conditions which allow for hybridization and polymerization to  
15 occur. A pair of probes, one corresponding to the 5' flanking region and the other corresponding to the 3' flanking region, would be sufficient to detect the nucleic acid molecules of the invention in a sample and may even be used to quantitate the amount present.

20 The invention also encompasses diagnostic kits for carrying out the methods disclosed above. In one embodiment, the diagnostic kit comprises (a) an APEX monoclonal antibody and (b) a conjugate of a specific binding partner for APEX antibody and a label for detecting bound antibody. In another embodiment, the diagnostic kit comprises a conjugate of a monoclonal antibody to the invention and a label capable of producing a  
25 detectable signal. The reagents may also include ancillary agents such as buffering agents and protein stabilizing agents, e.g. polysaccharides and the like. The diagnostic kit may further comprise, where necessary, other components of the signal-producing system including agents for reducing background interference, control reagents, an apparatus for conducting a test, etc. In another embodiment, the diagnostic kit comprises  
30 polynucleotide probes and a label capable of producing a detectable signal. Ancillary agents as mentioned above may also be present.

Therapeutic Uses of the Invention

5 Structural similarity in the context of sequences and motifs between APEX and proteins defined by CD antigens suggests that APEX proteins may be a potential target for diseases such as inflammation, cancer, and immune disorders. Therapeutic uses of APEX proteins include inhibition of leukocyte function in autoimmune diseases, inhibition of rejection of solid organ and bone marrow transplants (BMT), and inhibition of graft versus host disease following BMT. In the event that an anti-APEX antibody, such as  
10 anti-Apex-1 or anti-Apex-2 stimulates the immune system, therapeutic uses include but are not limited to immune system enhancement for vaccine development, oncological uses (anti-cancer immunotherapy), and immune deficiency syndromes including HIV.

In the treatment of cancer and immune disorders associated with decreased expression or  
15 activity of APEX, it is desirable to provide the protein, or to increase the expression or activity of APEX. In the treatment of above conditions associated with increased expression or activity of APEX, it is desirable to decrease the expression or activity of APEX. In certain diseases, APEX expression may remain constant, but using an agonist/antagonist may be therapeutically useful to modulate immune cell signaling.

20 The present invention provides a method for treating or preventing a disorder associated with decreased expression or activity of APEX in an individual. Examples of such disorders include, but are not limited to, immune disorders such as arteriosclerosis, asthma, arteriosclerosis, autoimmune anemia, acquired immunodeficiency syndrome  
25 (AIDS), bursitis, cholecystitis, cirrhosis, Crohn's disease; atopic dermatitis, diabetes mellitus, emphysema, atrophic gastritis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, psoriasis, Reiter's syndrome, rheumatoid arthritis, systemic lupus erythematosus; and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma,  
30 teratocarcinoma, cancers of adrenal gland, bladder, bone, bone marrow, breast, cervix, gall bladder, gastrointestinal tract, kidney, liver, lung, muscle, ovary, pancreas, prostate,

salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. The method comprises administering to such an individual a composition comprising a therapeutically effective amount of APEX or an agonist thereof. For example, a condition caused by a decrease in the standard or normal expression level of APEX in an individual, can be treated by  
5 administering to such an individual a pharmaceutical composition, comprising an amount of APEX polypeptide or an agonist, so as to increase the activity level of APEX in such an individual.

The present invention further provides a method for treating or preventing a disorder  
10 associated with increased expression or activity of APEX in an individual. Examples of such disorders include, but are not limited to those described above. The method of the invention comprises administering to such an individual a composition comprising a therapeutically effective amount of APEX antagonist. The preferred antagonists for use in the present invention are APEX-specific antibodies, antisense, or ribozyme molecules.  
15 The antisense molecules may be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Antisense oligonucleotides, specifically those that are derived from the transcription initiation site, e.g., between about -10 and +10 from the start site, are preferred to inhibit production of APEX.

In addition, ribozymes may also be used to catalyze the specific cleavage of RNA. The  
20 mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonuclease cleavage. For example, engineered hammerhead motif ribozyme molecules (Haselhoff and Gerlach (1988) *Nature* 334:585-591) may specifically and efficiently catalyze endonucleolytic  
25 cleavage of sequences encoding APEX.

In certain diseases, APEX expression may remain constant, but using an agonist/antagonist may be therapeutically useful to modulate immune cell signaling. For example, if APEX is a "negative" signaling molecule, an agonist is immunosuppressive.  
30 On the other hand, if APEX turns cells on, an antagonist is immunosuppressive. Thus,



APEX proteins may not be specifically involved in the disease, but manipulation of APEX signaling may be therapeutically beneficial.

5 The polynucleotides of the invention may also be used as reagents for treating a patient using the gene therapy approach. One method for *ex vivo* gene therapy may employ transplanting onto a patient, fibroblasts which are capable of expressing APEX polypeptides. Generally, fibroblasts are obtained from a subject by skin biopsy and infected with producer cells that produce infectious virus particles containing the *apex* gene of the invention. The producer cells for this method are prepared by transduction of  
10 packaging cells with a retroviral vector, e.g., Maloney murine sarcoma virus (MSV) containing the *apex* sequences. If the titer of the virus is high, then virtually all fibroblasts will be infected and no selection is needed. However, if the viral titer is low, then it is necessary to use a retroviral vector that has a selectable marker, such as neomycin. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine if  
15 the APEX protein is produced. The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on microcarrier beads.

Another aspect of present invention is using *in vivo* gene therapy methods to treat APEX-associated disorders, diseases, and conditions. The *in vivo* gene therapy relates to  
20 introduction of naked nucleic acid (DNA, RNA, or antisense DNA or RNA) corresponding to *apex* sequences into a host to increase or decrease the expression of APEX polypeptides. The *apex* polynucleotides may be operatively linked to a promoter or any other genetic elements that may be necessary for the expression of APEX proteins by the target tissue. Such gene therapy methods are known in the art (Tabata et al.,  
25 *Cardiovasc. Res.* (1997) 35:470-479, Wolff et al. (1997) *Neuromuscul. Disord.* 7:314-318, Schwarz et al. (1996) *Gene Ther.* 3:405-411). For a detailed description of the delivery techniques and gene therapy methods see U.S. Patents 5,693,622; 5,705,151; and 5,580,859.

30 Endogenous *apex* gene expression can also be reduced by inactivating or "knocking out" the desired *apex* gene and/or its promoter using targeted homologous recombination.

Methods for generating knock-out animals that fail to express a functional protein molecule are well known in the art (Capechi, *Science* (1989) 244:1288-1292, Thompson et al., *Cell* (1989) 5:313-321). Knock-out animals of the invention have uses which include, but are not limited to, animal model system useful for studying *in vivo* functions of APEX molecules, studying conditions and/or disorders associated with aberrant APEX expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

#### Pharmaceutical Compositions of the Invention

10

The invention includes pharmaceutical compositions for use in the treatment of APEX-associated diseases comprising a pharmaceutically effective amount of an APEX protein and a pharmaceutically acceptable carrier.

15

In one embodiment, the pharmaceutical compositions may comprise an APEX antibody, either unmodified, conjugated to a therapeutic agent (e.g., drug, toxin, enzyme or second antibody) or in a recombinant form (e.g., chimeric or bispecific). The compositions may additionally include other antibodies or conjugates (e.g., an antibody cocktail).

20

The antibody compositions of the invention can be administered using conventional modes of administration including, but not limited to, intravenous, intraperitoneal, oral, intralymphatic or administration directly into the tumor. Intravenous administration is preferred.

25

The compositions of the invention may be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred form depends upon the mode of administration and the therapeutic application.

30

The compositions also preferably include conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.

5

The most effective mode of administration and dosage regimen for the compositions of this invention depends upon the severity and course of the disease, the patient's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the compositions should be titrated to the individual patient.

10

The following examples are presented to illustrate the present invention and to assist one of ordinary skill in making and using the same. It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. It should be understood that these examples are for illustrative purposes only and are not intended in any way to otherwise limit the scope of the invention.

15

#### **EXAMPLE 1: Isolation and characterization of *apex-1***

##### **Production of GM-CSF/IL-4 Differentiated Monocyte and THP1 Cells**

20

Human monocytes were obtained from peripheral blood mononuclear cells by elutriation. The isolated monocytes were resuspended in RPMI 1640 medium containing 10% fetal bovine serum (Hyclone, Logan, UT) supplemented with penicillin/streptomycin, 2 mM glutamine, 1% non-essential amino acids, 1 mM sodium pyruvate IL-4 (75 ng/ml) and GM-CSF (15 ng/ml) (each from Gibco BRL, Grand Island, NY) at a cell concentration of  $5 \times 10^5$ /ml. Cells were incubated in tissue culture flasks at 37°C, 5% CO<sub>2</sub> for seven days. Following the incubation period, the non-adherent cells were removed from the flask.

25

THP1 human monocytes were grown to a final concentration of  $5 \times 10^5$  cells/ml in RPMI 1640 medium containing 10% fetal bovine serum supplemented with penicillin/streptomycin and 2mM glutamine.

- 5 GM-CSF/IL-4 differentiated human peripheral blood mononuclear cells ( $2 \times 10^8$ ) and THP1 human monocytes ( $2 \times 10^8$ ) were washed twice with PBS (Gibco BRL) at 4°C.

#### RNA isolation

- 10  $2 \times 10^8$  GM-CSF/IL-4 differentiated human peripheral blood mononuclear cells and  $2 \times 10^8$  THP1 human monocytes were washed twice with PBS (Gibco BRL, Grand Island, NY) at 4° Celsius. Poly A+RNA was isolated directly using Fast Track 2.0™ (Invitrogen, Carlsbad, CA).

#### 15 Construction of the Subtraction Library

- The PCR-select cDNA subtraction kit™ (Clontech, Palo Alto, CA) was used to generate a subtraction library from GM-CSF/IL-4 human monocyte poly A+ RNA (tester) and THP1 human monocyte poly A+ RNA (driver). Ten secondary PCR reactions were  
20 combined and run on a 2% agarose gel. Fragments ranging from approximately 0.3kb – 1.5 kb were gel purified using the QIAgen gel extraction kit (QIAgen Inc., Valencia, CA) and inserted into the TA cloning vector, pCR2.1 (Invitrogen). TOP10F' competent *E. coli* (Invitrogen) were transformed and plated on LB plates containing 50 micrograms/ml ampicillin. Clones were isolated and grown in LB broth containing similar  
25 concentrations of ampicillin. Plasmid DNAs were sequenced using standard techniques.

- A 367 bp clone was isolated and found to have homology to the 5' region of several members of the CD2 subgroup of the Ig superfamily. A clone which included the remaining sequence of *apex-1* was isolated by 3' PCR amplification using gene specific  
30 primers, such as JNF primers (see below). The selection of the sequences of the JNF primers was based on a consensus sequence of an aligned contig sequence that was

generated by overlapping the sequences of six public ESTs (EST database) (AA381714, H73135, AA554342, H74227, AA921765, AA765813).

### 3'-Rapid Amplification of cDNA ends

5

In an effort to isolate clones that included the remaining 3'untranslated region (3'-UTR) of *apex-1*, rapid amplification of the 3' ends of *apex-1* cDNA was performed using 3'-RACE PCR technology.

10 First strand cDNA was synthesized from GM-CSF/IL-4 differentiated mRNA using a hybrid oligo dT primer (Zhang, Y. and Frohman, M. A. 1997 *Methods Mol. Biol.* 69:61-87), termed JNF3 (5'-cca gtg agc aga gtg acg agg act cga gct caa gct ttt ttt ttt ttt t-3') (SEQ ID NO.: 9) and the Superscript pre-amplification system (Gibco BRL, Grand Island, NY). To amplify *apex-1* 3'-end sequences, gene-specific primers JNF1 and JNF2  
15 were paired with JNF4 and JNF5, respectively. First round amplification using JNF1 (5'-cag agt acg aca caa tcc c-3') (SEQ ID NO.: 7) and JNF4 (5'-gag gac tcg agc tca agc-3') (SEQ ID NO.: 10) was done using 25 cycles at 94 degrees C, 30 sec; 57 degrees C, 30 sec; and 72 degrees C, 1 min. Primary reactions were diluted 50 fold and used in secondary amplification with JNF2 (5'-act cca ctg tgg aaa tac cg-3') (SEQ ID NO.: 8) and  
20 JNF5 (5'-cca gtg agc aga gtg acg-3') (SEQ ID NO.: 11). JNF1/JNF4 and JNF2/JNF5 amplimers were gel-purified and cloned into pCR2.1 (Invitrogen). The JNF2/JNF5 primer-pair generated an amplimer product that is 1753 bp and spans the remaining translated and 3'-untranslated regions of *apex-1*.

25 A full-length contig sequence of *apex-1* was generated by aligning the 1753 bp sequence with the 1336 bp contig sequence. A 2704 bp clone which includes the full-length sequence of *apex-1* cDNA was isolated by PCR amplification of GM-CSF/IL-4 cDNA using the primer pair Llewellyn4 (5'-ccc aag ctt cca gag agc aat atg gct ggt cc-3') (SEQ ID NO.:21) and JNF4 (SEQ ID NO.:10). The full-length fragment was cloned into  
30 pCR2.1 and sequenced.

One clone was found to have significant identity with several members of the Ig superfamily CD2 subgroup including CD84 (38%), Ly9 (37%), SLAM (31%).

#### **Transcript expression of *apex-1* in various cell lines**

5

Several cell lines and human leukocyte populations were analyzed for expression of *apex-1* transcripts using RT-PCR analysis. Total RNA was isolated from various B and T cell lines and freshly purified neutrophils. Specifically, total RNA was isolated from brain, heart, lung, liver, kidney, pancreas, small intestine, ovary, testis, prostate, placenta, skeletal muscle, spleen, thymus, bone marrow, tonsil, lymph node, leukocyte, and fetal liver. Additionally, total RNA was isolated from resting T cells, a B cell line (TJ), THP1 monocytes, monocytes stimulated with GM-CSF and IL-4, unactivated NK cells, and unactivated PMN cells.

10

First-strand cDNA was synthesized using the Superscript Preamplification System (Gibco BRL, Grand Island, NY), as described in the section above. As controls, expression of *apex-1* transcripts was tested in GM-CSF/IL-4 differentiated human monocytes (e.g., detectable levels) and THP1 (e.g., no detectable levels). The primers JNF6 (5'-atc ctt tgg cag ctc aca gg-3') (SEQ ID NO.:12) and JNF7 (5'-ctt cac aga gct tcc tgg c-3') (SEQ ID NO.:13) were used to amplify a 613 bp fragment from cDNA that were generated using Superscript Preamplification Kit™ (Gibco BRL, Grand Island, NY).

20

#### **Northern Analysis**

The presence of *apex-1* transcripts in various tissues was analyzed by Northern analysis using multiple tissue northern membranes (Human MTNI #7760-1; Human Immune System MTNII #7768-1) purchased from Clontech Laboratories (Palo Alto, CA). The *apex-1* transcripts were detected by hybridization with [<sup>32</sup>P]dCTP-radiolabeled (NEN, Boston, MA) random-primed 368 bp *apex-1* cDNA probe. The membranes were washed under high stringency conditions (0.1X SSC/0.1%SDS at 65°C) and exposed for 48 hours at -80 °C. The results of the Northern blot is shown in Figure 8.

30

### Results:

A full-length cDNA clone which includes the human *apex-1* sequence was isolated by  
5 PCR amplification of transcripts from a subtraction library that was constructed from  
GM-CSF/IL-4 differentiated human monocytes minus THP1 human monocyte cell line.

The nucleotide sequence of *apex-1* (Figure 2) includes an open reading frame (ORF) that  
is predicted to encode a protein 335 amino acid in length that exhibits structural  
10 properties shared by members of the CD2 subfamily (Hahn, W. C., et al., 1993 Chapter 5,  
in: *Lymphocyte Adhesion Molecules*, ed. Shimizu, Y.). This nucleotide sequence is  
predicted to encode the APEX-1 protein that includes an N-terminal 22 amino acid  
hydrophobic signal peptide, a 203 amino acid extracellular domain, a 24 amino acid  
residue transmembrane domain, and an 86 amino acid intracellular domain (see Figure 5).  
15 The extracellular domain has two Ig-like regions (V-tC2). The V region lacks the typical  
disulfide bonds, while the C2 region includes two conserved disulfide bridges. There are  
six potential N-glycosylation sites in the extracellular domain of the sequence N-X-S/T.  
The intracellular domain includes four tyrosines. Two of the four tyrosines are predicted  
to form two different SH2 domain binding motifs (Songyang, Z., et al., (1993) *Cell*  
20 72:767-778; Songyang, Z., et al., (1994) *Molec. Cell. Biol.* 14:2777-2785). Diversity in  
the two other tyrosine signaling motifs indicates that APEX-1 may bind a diverse range  
of kinases.

A data base search for *apex-1* related nucleotide sequences demonstrated significant  
25 sequence homologies with AJ271869, Z51572 (PCT WO2000011150-A1), Z49571 and  
Z49572 (PCT WO9967387-A2), Z65041 (PCT 9963088-A2), X41503 (PCT  
WO9906553-A2), and X00615 (PCT WO9842738-A1). APEX-1 shares structural  
similarities with members of the CD2 family. Thus, it is postulated that APEX-1 is a  
cell-surface receptor that regulates adhesion and generates co-stimulatory signals to  
30 mediate leukocyte proliferation, differentiation, migration, or activation. It is possible  
that APEX-1 enhances antigen-specific proliferation and cytokine production, similar to

SLAM which is another member of the CD2 subfamily. Thus, APEX-1 may prove to be a potential target for diseases with an inflammatory and autoimmune component indicating that the *apex-1* gene encodes a protein that belongs to the Ig superfamily and may be involved in ligand binding and transmitting signals from the cell surface.

5

The RNA transcript pattern of *apex-1* was analyzed by Northern blot of immune and non-immune tissues and revealed the expression of two *apex-1* transcripts, measuring 2.7 kb and 1.5 kb in length (Figure 8). Relatively high levels of the 2.7 kb transcript was detectable in immune tissue, such as spleen and lymph node (Figure 8 A). Lower levels were detectable in peripheral blood lymphocytes (PBL), and very low levels were detectable in bone marrow. In contrast, the 1.5 kb transcript was detectable in both immune and non-immune tissues. Relatively high levels of the 1.5 kb transcript was detectable in spleen, lymph node and PBL. Significantly lower levels of the 1.5 kb transcript was detectable in heart, lung, and placenta (Figure 8 B).

15

The transcript expression of *apex-1* was analyzed in several cell lines and human leukocyte populations by RT-PCR analysis using gene-specific primers that hybridize to the region of *apex-1* that encodes the extracellular domain. Transcripts of *apex-1* were detectable in cells from tonsil, lymph nodes, whole leukocytes, resting T cells and NK cells, but were not expressed in fresh neutrophils or the THP-1 cell line. Monocytes stimulated with GM-CSF and IL-4 as well as a B cell line (e.g., TJ is from a normal human subject) expressed *apex-1* transcripts (Figure 9).

20

These results suggest that *apex-1* is a new member of the Ig superfamily, which may be involved in transducing signals to APEX-1-expressing cells.

25

## **EXAMPLE 2: Isolation and characterization of *apex-2***

### **Production of HSP70-treated cells**



The 70Z/3 murine pre B-cells were grown to a density of  $5 \times 10^5$  cells/ml and treated with 1 $\mu$ g/ml HSP70 (200 $\mu$ g total) for 1 hour. The cells were harvested and washed. Similar numbers of untreated cells were harvested.

## 5 RNA Isolation

Poly A+ RNA was isolated directly from the HSP70-treated and non-treated 70Z/3 cells using the Fast Track 2.0 kit™ (Invitrogen, Carlsbad, CA).

## 10 Construction of the Subtraction Library

The PCR-select cDNA subtraction kit™ (Clontech, Palo Alto, CA) was used to generate a subtraction library from untreated 70Z/3 poly A+ RNA (tester) and HSP70-treated 70Z/3 poly A+ RNA (driver). Secondary PCR reactions were combined and run on a 2% agarose gel. Fragments ranging from approximately 0.3kb – 1.5 kb were gel purified using the QIAgen gel extraction kit (QIAgen Inc., Valencia, CA) and inserted into the TA cloning vector, pCR2.1 (Invitrogen). TOP10F' competent *E. coli* (Invitrogen) were transformed and plated on LB plates containing 50 micrograms/ml ampicillin. Plasmids were isolated using QIAgen miniprep spin (QIAgen) and sequenced using ABI cycle sequencers (ABI Prism, PE Applied Biosystems).

A 958 bp cDNA clone was isolated which included the sequence of the 3' region of *apex-2*. The remainder of the *apex-2* sequence was isolated by 5'-RACE PCR using the primer that was supplied by the kit and two gene-specific primers (e.g., JNF)

## 25 5'-Rapid Amplification of *apex-2*

A DNA fragment, which included the sequence of the 5' region of *apex-2*, was isolated using HSP70-treated murine 70Z/3 cDNA and the MARATHON RACE amplification kit from Clontech Laboratories (Palo Alto, CA). The gene-specific primer JNF22 (5'-tta acc ttc agg gta atg gg-3') (SEQ ID NO.:25) and JNF23 (5'-gaa caa tgc aaa tgg cag cg-3') (SEQ

ID NO.:26), and the AP1 primer provided by the MARATHON RACE kit were used to amplify fragments that included sequences in the 5' region of *apex-2*. The 5' amplicon fragment, resulting from the AP1/JNF22 primer pair was ligated to the 958 bp fragment thereby generating a full length cDNA clone of *apex-2*. A sequence analysis showed that *apex-2* is homologous to members of the CD2 subgroup of the Ig superfamily, such as CD84, Ly9, 2B4.

### Results:

- 10 A full length cDNA clone which includes the murine *apex-2* sequence was isolated by PCR amplification of transcripts from a murine subtraction library that was constructed from untreated murine 70Z/3 poly A+ RNA minus murine HSP70-treated 70Z/3 poly A+ RNA.
- 15 The nucleotide sequence of *apex-2* (Figure 3) includes an open-reading frame that is predicted to encode a protein 351 amino acids in length that exhibits structural properties shared by members of the CD2 subfamily. The predicted APEX-2 protein includes a putative signal peptide of 29 amino acids, a 210 amino acid extracellular domain or region, a 23 amino acid internal hydrophobic segment that represents a transmembrane domain, and an 89 amino acid intracellular (e.g., cytoplasmic) domain (Figure 6). The extracellular portion is predicted to have two Ig-like domains (a V-set and a C2-set). The predicted extracellular domain has nine Asn-linked glycosylation sites. The predicted cytoplasmic domain has 3 potential SH2 domain binding motifs (YAQV, YSIV, YNQP). The first two motifs may be involved in binding to SHP-2. A database search for *apex-2* related sequences demonstrated significant sequence homologies of *apex-2* with AF248634 and AF248636 (EMBL/GenBank/DDBJ, submitted March, 21, 2000)

APEX-2 shares structural similarities with members of the CD2 family. Thus, like APEX-1, it is postulated that APEX-2 is a cell-surface receptor that regulates adhesion and generates co-stimulatory signals to mediate leukocyte proliferation, differentiation, migration, or activation. It is possible that APEX-2 enhances antigen-specific

proliferation and cytokine production, similar to SLAM which is another member of the CD2 subfamily. Thus, APEX-2 may prove to be a potential target for diseases with an inflammatory and autoimmune component indicating that the *apex-2* gene encodes a protein that belongs to the Ig superfamily and may be involved in ligand binding and transmitting signals from the cell surface.

### EXAMPLE 3: Obtaining and Characterizing *apex-3*

The predicted amino acid sequence of murine APEX-2 was used to search proprietary (e.g., Incyte Pharmaceutical) and public (EST database) databases. Two clusters of EST sequences were identified as having considerable homology to murine APEX-2. The first cluster contained 20 overlapping clones from the Incyte database, while the second contained 14 overlapping clones from the EST database. The contig encodes an open reading frame that is homologous to APEX-1, APEX-2, CD84, SLAM and CD48.

Samples of two EST clones, each containing full-length *apex-3* sequences, were obtained from a proprietary database and the clones were sequenced. The nucleotide sequence of *apex-3* (Figure 4) includes an open reading frame having homology to *apex-2*, *apex-1*, CD84, SLAM and CD48. The nucleotide sequence of *apex-3* is predicted to encode a type-1 trans-membrane protein. APEX-3 includes two Ig-like domains (V-set and C2-set). These are similar to those described previously for APEX-1 and APEX-2. APEX-3 includes: a 22 amino acid signal sequence beginning with the first methionine; an internal hydrophobic segment of 23 amino acids characterizes the putative transmembrane domain and splits the mature protein into two segments; the putative extracellular domain consists of 209 amino acids; and includes 3 potential Asn-glycosylation sites (Figure 7). The putative cytoplasmic domain is much shorter (31 amino acids) than that seen with other CD2 subgroup members and does not include any SH2-domain binding motifs.

A database search of *apex-3* related sequences identified two sequences, Z238457 (PCT WO9940184-A1) and A09042 (PCT WO20001880-A1) that demonstrated significant homology with *apex-3*.

APEX-3 shares structural similarities with members of the CD2 family. Thus, like APEX-1, it is postulated that APEX-3 is a cell-surface receptor that regulates adhesion and generates co-stimulatory signals to mediate leukocyte proliferation, differentiation, migration, or activation. It is possible that APEX-3 enhances antigen-specific proliferation and cytokine production, similar to SLAM which is another member of the CD2 subfamily. Thus, APEX-3 may prove to be a potential target for diseases with an inflammatory and autoimmune component indicating that the *apex-3* gene encodes a protein that belongs to the Ig superfamily and may be involved in ligand binding and transmitting signals from the cell surface.

#### EXAMPLE 4: Expression of APEX-1Ig and APEX-2mIg fusion proteins

##### Construction of *apex-1*Ig Expression Plasmid:

A fusion protein including the putative extracellular domains of APEX-1 and human IgG1, (Apex-1Ig) was produced. cDNA fragments corresponding to the Apex domains were obtained by PCR (forward primer HIIIDS4fp CCC AAG CTT CCA GAG AGC AAT ATG GCT GGT TCC (SEQ ID NO.:35); reverse primer DS4Bamrp C GCG GAT CCG AGG AAT CTG GGT CAT CAG CAG CAC C (SEQ ID NO.:36), PCR product cut with HindIII and BamHI restriction endonucleases), and joined to a cDNA fragment encoding the hinge (H), CH<sub>2</sub> and CH<sub>3</sub> domains of human IgG1 in the vector pCDM7 which was likewise digested with HindIII and BamHI restriction endonucleases) (Starling, G.C et. al. (1996) *Eur. J. Immunol.*26:738-46). Ligated products were used to transform MC1061/P3 *E. coli*, which were grown on agar containing 50ug/ml ampicillin and 15 ug/ml tetracyclin and colonies screened for the appropriate plasmids. Cloned cDNAs were obtained from the bacteria by standard SDS lysis and purification on QIAGEN miniprep columns. The integrity APEX-1-encoding portion of *apex-1*Ig cDNA clone was confirmed by sequencing. The resulting amino acid sequence of the expressed protein contributed to by the *apex-1* cDNA is shown (Figure 10). The amino terminal secretory sequence was derived from the endogenous *apex-1* gene, and the amino acids 1-

- 225 of APEX-1 are present (Figure 2). The BamHI enzyme digestion site adds His<sub>226</sub>-Pro<sub>227</sub> amino acids at the junction of the APEX-1 sequence and the H-CH<sub>2</sub>-CH<sub>3</sub> Ig portion of the molecule. This construct contained a Thrombin cleavage site which was located immediately C-terminal to the His-Pro residues (Hollenbaugh et al., *J. Immunol. Methods* (1995) 188: 1-7) to enable separation of APEX-1 extracellular domain from human IgG1 sequence.

#### **Construction of Apex-2mIg Expression Plasmid:**

- 10 The Apex-2mIg expression plasmid including the entire extracellular domain of Apex-2 obtained by PCR (forward primer Apex2Kpn1FP CCG GGT ACC AAC AGA AAG TCT CAG CGA CAA (SEQ ID NO.:37), reverse primer Apex2BamRP CGC GGA TCC CAG GGT GGA TTA GTT AGA AC (SEQ ID NO.:38), PCR product cut with Kpn1 and BamHI restriction endonucleases), and joined to a cDNA fragment encoding the hinge  
15 (H), CH<sub>2</sub> and CH<sub>3</sub> domains of murine IgG2a in the vector pCDM7 which was likewise digested with Kpn1 and BamHI restriction endonucleases. Ligated products were used to transform MC1061/P3 E. coli, which were grown on agar containing 50ug/ml ampicillin and 15 ug/ml tetracyclin. Cloned cDNAs were obtained from the bacteria by standard SDS lysis and purification on QIAGEN miniprep columns. The integrity of APEX-2 -  
20 encoding portion of the *apex-2mIg* cDNA clone was confirmed by sequencing. The resulting amino acid sequence of the expressed protein contributed to by the Apex-2 cDNA is shown (Figure 11). The amino terminal secretory sequence was derived from the endogenous *apex-2* gene, and the amino acids 1-238 of APEX-2 are present (Figure 3). The BamHI endonuclease restriction site adds His-Pro amino acids at the junction of  
25 the APEX-2 and the H-CH<sub>2</sub>-CH<sub>3</sub> Ig portion of the molecule.

#### **Expression of APEX-1Ig and APEX-2mIg in COS Cells:**

- The fusion proteins, APEX-1Ig, including the putative extracellular domains of APEX-1  
30 and human Ig, and APEX-2mIg, consisting of the putative extracellular domain of APEX-2 and mouse Ig were produced by transient expression of COS cells in cell

factories (Nunc, Roskilde, Denmark) in serum free-DMEM supplemented with 2 mM glutamine. COS cells were grown to approximately 75% confluency in cell factories in DMEM containing 10% fetal bovine serum (FBS). Transient expression of Apex-1Ig and Apex-2mIg was obtained by transfection using the DEAE-Dextran/Chloroquine and purified fusion-protein-encoding vector. DMEM containing 5% Nu-Serum (Becton-Dickinson, Franklin Lakes, NJ), 1ug/ml DNA, and DEAE-Dextran/Chloroquine at a final concentration of 400ug/ml DEAE-Dextran and 100uM Chloroquine phosphate was added to cells for 4 h at 37 C in a total volume of 625 ml. Cells were DMSO shocked (1000 ml of 10% DMSO in PBS) for 2 min, prior to overnight culture in 1000 ml of 10% FBS/DMEM. DMEM (1000 ml/factory) supplemented with 2 mM glutamine was substituted at day 1. Cells were cultured in serum-free DMEM for 3 days, and cell-free supernatants were harvested.

The recombinant APEX-1Ig or APEX-2mIg fusion proteins were purified by adsorption to and elution from Protein A Sepharose. Briefly, after removal of cellular debris by low speed centrifugation, medium was applied to a column (approximately 1000 ml of medium/2 ml packed bed volume) of immobilized protein A (Repligen, Cambridge, MA) equilibrated with phosphate buffered saline (PBS). After application of the medium, the column was washed with PBS and subsequently binding buffer compatible with the elution buffer (Pierce, Rockford, IL), and bound protein was eluted with 15 ml of ImmunoPure Gentle Ag/Ab Elution Buffer (Pierce). Eluted material was both dialyzed against PBS and concentrated in 15 ml Biomax 10K NMWL Ultrafree 15 centrifugal filter device (Millipore Corporation, Bedford, MA). Protein concentrations were determined using Coomassie Plus Protein Assay Reagent (Pierce, IL). The purified APEX-1Ig and APEX-2mIg proteins were analyzed by SDS-PAGE. APEX-1Ig had slightly higher electrophoretic mobility than APEX-2mIg (Figure 12).

The human IgG1 construct included an amino-terminal thrombin cleavage site (Hollenbaugh et al., 1995), allowing separation of APEX-1 extracellular domain from IgG1. IgG1 was cleaved with thrombin (Sigma, St. Louis, MO) at 50:1 (w/w) Apex-1Ig:thrombin ratio for 1 hour at room temperature. Free IgG1 and non-cleaved Apex-1Ig

were removed by adsorption to protein A and purified APEX-1 protein was further characterized by Western Blot analysis (described below, Figure 14) using the monoclonal antibodies prepared by the invention (described in Example 5).

5     **Expression of APEX-1Ig in Sf9 cells:**

The cDNA encoding the APEX-1Ig (described above) was cloned into a modified pFastbac vector (Gibco-BRL Life Technologies, Gaithersburg, MD) for baculovirus expression in Sf9 (*Spodoptera frugiperda*) insect cells. The entire Apex-1Ig cDNA was  
10     excised using HindIII and XbaI restriction endonucleases, and ligated into the modified pFastbac vector cut with HindIII and XbaI. A Recombinant virus was obtained following transformation of DH10 Bac cells with pFastbac-Apex-1hIg vector. Sf9 cells ( $2 \times 10^6$ /ml) were infected with the recombinant virus (1/1000 dilution of PIII virus stock) and grown for 24 hr at 27 C in EX-CELL 420 insect serum free medium (JRH  
15     Bioscience, Lenexa, KS). Cell free-supernatant was collected and passed over protein A-sepharose to purify the APEX-1Ig. APEX-1Ig produced by Sf9 cells had slightly increased electrophoretic mobility than that of APEX-1Ig produced by COS cells (Figure 13), probably due to differences in protein glycosylation in the two expression systems.

20     **Western Blot Analysis:**

APEX-1 extracellular domain (1ug/lane) was pretreated in sample buffer with (reduced) or without (non-reduced) 2-mercaptoethanol, boiled for 5 min and loaded onto 4-20% Tris/Glycine gels (Novex, San Diego, CA) for SDS-PAGE. Following electrophoresis,  
25     proteins were transferred onto nitrocellulose membranes (BioRad, San Diego, CA). Membranes were blocked overnight in 5% non-fat milk powder/0.1% Tween-20/Tris buffered saline (T-TBS). Anti-APEX-1 mAb (hybridoma culture supernatant) were used to detect the extracellular domain of APEX-1. Bound antibody was visualized using HRP-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch, Inc., West Grove,  
30     PA) and the Enhanced Chemiluminescence reagent (Amersham, Arlington Heights, IL) with Kodak X-Omat film.

## **Results**

Fusion proteins including the extracellular domains of APEX-1 and APEX-2 fused to either human IgG1 (APEX-1Ig) or mouse IgG2a (APEX-2mIg) were produced as described above. Under reducing conditions, APEX-1Ig exhibited a molecular mass of 75-80 kDa, with APEX-2mIg migrating slightly faster corresponding to a molecular mass of 70-75kDa (Figure 12). Monoclonal antibodies against APEX-1 raised by immunizing mice with the APEX-1 recombinant extracellular domains, produced by cleavage of APEX-1Ig with thrombin, were used for Western Blot analysis of recombinant APEX-1Ig fusion protein so produced. The extracellular domain exhibited a molecular weight of approximately 80kDa under non-reducing conditions, and 40kDa under reducing conditions, indicating the presence of disulfide bonds in the extracellular domain as produced by the cleaved fusion protein. The extracellular domain was recognized by a panel of monoclonal antibodies against APEX-1 (Figure 14).

### **EXAMPLE 5: Monoclonal Antibody preparation**

Female BALB/c mice were injected intraperitoneally at day 0 and day 21 with recombinant, COS produced, full-length extracellular domain of Apex-1 (50 µg) in RIBI adjuvant (Ribi Immunochem Research, Inc, Hamilton, MT). At day 31, serum (100µl) was obtained to test for the presence of specific antibodies. At day 35, the mice received a final injection i.v. of 50µg in PBS of Apex-1 protein. Three days after the last injection, mice were sacrificed and spleen cells were fused to the X63-Ag8-653 myeloma fusion partner at a ratio of 5:1 using 50% polyethylene glycol as previously described (Starling et. al. 1996). The fused cells were resuspended in complete IMDM medium supplemented with 2 mM glutamine, hypoxanthine (0.1 mM), aminopterin (0.01 mM), thymidine (0.016 mM) and 10% ORIGEN hybridoma cloning factor (IGEN International, Inc. Gaithersburg, MD). The fused cells were then distributed between the wells of 96-well tissue culture plates, so that each well contained 1 growing hybrid on average.



After 10-14 days the supernatants of the hybridoma populations were screened for specific antibody production. Cells were grown and wells assayed for binding activity to Apex-1 but not an irrelevant human Ig fusion protein to remove reactivity against contaminating human Ig-specific hybridoma cells. Hybridoma cells secreting Apex-1Ig specific mAb were cloned (once) by limiting dilution (in IMDM containing 10% ORIGIN cloning factor and 2 mM glutamine) and expanded in tissue culture plates. Tissue culture supernatants were used as a source of unpurified mAb for western blotting experiments.

#### 10 **EXAMPLE 6: Expression of full-length APEX-1 and APEX-2 Polypeptides**

*apex-1* and *apex-2* cDNAs encoding for the full length mature polypeptides (excluding the sequences encoding native signal sequences) were cloned into pCDNA3 (Invitrogen, Carlsbad, CA) with cDNA encoding for the human CD5 signal peptide (Accession # X04391, amino acid sequence MPMGSLQPLATLYLLGMLVASCLG) and the FLAG tag peptide (DYKDDDDK) 5' to the Apex sequence. FLAG sequences were added to the forward (5') primers, to generate sequences including the following, CD5 Signal peptide-FLAG-APEX-1, and CD5 Signal peptide-FLAG-APEX-2-encoding sequences. The cDNAs were generated by PCR using primer sequences for *apex-1*: forward primer SpeFlagA1fp CGG ACT AGT GAC TAC AAG GAC GAC GAT GAC AAG TCT GGA CCC GTG AAA GAG CTG GTC GGT TCC (SEQ ID NO.:39), reverse primer A1Xbarp tgc tct aga cac tgc tgt cta gat aac att ctc ata ggc (SEQ ID NO.:40); *apex-2* forward primer SpeFlagA2fp CGG ACT AGT GAC TAC AAG GAC GAC GAT GAC AAG AGT GAA GTT TCA CAG AGC AGC TCA GAC CCC (SEQ ID NO.:41), reverse primer A2xbarp tgc tct aga caa gtc act gca gtg ctc ttc ctt cag gag (SEQ ID NO.:42). PCR products were digested with the restriction endonucleases SpeI and XbaI and ligated to pCDNA3 that had been digested with SpeI and XbaI. Ligated products were used to transform DH5a *E. coli*, which were grown on agar containing 100ug/ml ampicillin. Cloned cDNAs were obtained from the bacteria by standard SDS lysis and purification on QIAGEN miniprep columns. The DNAs were sequenced to ensure fidelity of the PCR reaction. The encoded amino acid sequences of Flag-APEX-1 and Flag-APEX-2 are shown in Figures

15 and 16 respectively. The cDNAs were transfected into COS cells for transient expression or into human or mouse cell lines for stable expression using the antibiotic geneticin (Gibco-BRL Life Technologies) as a selection agent.

- 5 Cell surface expression can be detected by binding of specific antibody to either APEX-1 or APEX-2, or by M2 antibody (Sigma, St. Louis, MO) against the FLAG tag.

#### **EXAMPLE 7: Polyclonal antibody production**

- 10 NZW rabbits were immunized with either the extracellular domains of Apex-1 or Apex-2mIg in Freund's Complete Adjuvant (initial immunization) or Freund's Incomplete Adjuvant (boosts). Following a series of immunizations, rabbits were bleed and sera were collected and processed by centrifugation. Sera will be adsorbed against human and mouse immunoglobulins to remove antibody recognizing the Ig portion of the fusion  
15 proteins used as immunogens. Antisera are to be used in functional studies and for cell surface staining.

Various publications are cited herein that are hereby incorporated by reference in their entirety.

- 20 As will be apparent to those skilled in the art in which the invention is addressed, the present invention may be embodied in forms other than those specifically disclosed without departing from the spirit or potential characteristics of the invention. Particular embodiments of the present invention described above are therefore to be considered in all respects as illustrative and not restrictive. The scope of the invention is as set forth in the appended claims and  
25 equivalents thereof, rather than being limited to the examples contained in the foregoing description.

**REFERENCES:**

1. Hahn, William et al., "CD2: A Multifunctional Coreceptor Involved in T-Cell Adhesion and Activation," *Lymphocyte Adhesion Molecules*, 1993, Chap. 5:105-32.
2. Williams, Alan F. and A. Neil Barclay, "The Immunoglobulin Superfamily—Domains for Cell Surface Recognition," *Ann. Rev. Immunol.*, 1988, 6:381-405.
3. Dustin, Michael L. and Timothy A. Springer, "Role of Lymphocyte Adhesion Receptors in Transient Interactions and Cell Locomotion," *Ann. Rev. Immunol.*, 1991, 9:27-66.
4. Wingren, Anette Gjörlöf et al., "T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles," *Critical Reviews in Immunology*, 1995, 15(3&4):235-53.
5. Songyang, Zhou et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," *Cell*, March 12, 1993, 72:767-78.
6. Cocks, Benjamin G. et al., "A Novel Receptor Involved in T-Cell Activation," *Nature*, July 20, 1995, 376:260-3.
7. De la Fuente, Miguel Angel et al., "CD84 Leukocyte Antigen is a New Member of the Ig Superfamily," *Blood*, September 15, 1997, 90:2398-2405.
8. Songyang, Z. et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," *Molecular and Cellular Biology*, April 1994, 14(4):2777-85.

## SEQUENCE LISTING

<110> Starling, Gary  
Finger, Joshua N.

5

<120> NOVEL IMMUNOGLOBULIN SUPERFAMILY MEMBERS APEX-1, APEX-2,  
APEX-3

<130> 30436.43USP1

10

<140> Not yet known

<141> 1999-12-15

<160> 34

15

<170> PatentIn Ver. 2.0

<210> 1

<211> 2704

20

<212> DNA

<213> APEX-1

<400> 1

25	ggaagtggct	tcatttcagt	ggctgacttc	cagagagcaa	tatggctggt	tccccaacat	60
	gcctcaccct	catctatata	ctttggcagc	tcacagggtc	agcagcctct	ggacccgtga	120
	aagagctggt	cggttcctgt	gggtggggccg	tgactttccc	cctgaagtcc	aaagtaaagc	180
	aagttgactc	tattgtctgg	accttcaaca	caaccctctc	tgtcaccata	cagccagaag	240
	ggggcactat	catagtgaac	caaaatcgta	atagggagag	agtagacttc	ccagatggag	300
	gctactccct	gaagctcagc	aaactgaaga	agaatgactc	agggatctac	tatgtgggga	360
30	tatacagctc	atcactccag	cagccctcca	cccaggagta	cgtgctgcat	gtctacgagc	420
	acctgtcaaa	gcctaaagtc	accatgggtc	tgacagagcaa	taagaatggc	acctgtgtga	480
	ccaatctgac	atgctgcatg	gaacatgggg	aagaggatgt	gatttatacc	tgggaaggccc	540
	tggggcaagc	agccaatgag	tcccataatg	ggtccatcct	ccccatctcc	tggagatggg	600
	gagaaagtga	tatgaccttc	atctgcgttg	ccaggaaacc	tgtcagcaga	aacttctcaa	660
35	gccccatcct	tgccaggaag	ctctgtgaag	gtgctgctga	tgaccagat	tcctccatgg	720
	tcctcctgtg	tctcctgttg	gtgccccctc	tgtcagctct	ctttgtactg	gggctatttc	780
	tttggtttct	gaagagagag	agacaagaag	agtacattga	agagaagaag	agagtggaca	840
	tttgcggga	aactcctaac	atatgcccc	attctggaga	gaacacagag	tacgacacaa	900
	tccctcacac	taatagaaca	atcctaagg	aagatccagc	aaatacgggt	tactccactg	960
40	tggaaatacc	gaaaaagatg	gaaaatcccc	actcactgct	cacgatgcca	gacacaccaa	1020
	ggctatttgc	ctatgagaat	gttatctaga	cagcagtgc	ctcccctaag	tctctgtctc	1080
	aaaaaaaaac	aattctcggc	ccaaagaaaa	caatcagaag	aattcactga	tttgactaga	1140
	aacatcaagg	agaatgaag	aacgttgact	ttttccagg	ataaattatc	tctgatgttt	1200
	cttttagattt	aagagttcgt	aattccatcc	actgctgaga	aatctcctca	aaccagaag	1260
45	gtttaatcac	ttcatcccaa	aaatgggatt	gtgaatgtca	gcaaaccata	aaaaagtgc	1320
	ttagaagtat	tcctatagaa	atgtaaatgc	aaggtcacac	atattaatga	cagcctgttg	1380
	tattaatgat	ggctccaggt	cagtgtctgg	agtttcatc	catcccagg	cttggtgtc	1440
	aggattatac	caagagtctt	gctaccagga	gggcaagaag	acaaaaacag	acagacaagt	1500
	ccagcagaag	cagatgcacc	tgacaaaaat	ggatgtatta	attggctcta	taaaactatg	1560
50	gcccagcact	atgctgagct	tacactaatt	ggtcagacgt	gctgtctgcc	ctcatgaaat	1620
	tggctccaaa	tgaatgaact	actttcatga	gcagttgtag	caggcctgac	cacagattcc	1680
	cagagggcc	ggtgtggatc	cacaggactt	gaagggtcaa	gttcacaaag	atgaagaatc	1740
	agggtagctg	accatgtttg	gcagatacta	taatggagac	acagaagtgt	gcatggccca	1800
	aggacaagga	cctccagcca	ggcttcattt	atgcacttgt	gctgcaaaag	aaaagtctag	1860
55	gttttaaggc	tgtgccagaa	ccatcccaa	taaagagacc	gagtctgaag	tcacattgta	1920
	aatctagtgt	aggagacttg	gagtcaggca	gtgagactgg	tggggcacgg	ggggcagtgg	1980
	gtacttgtaa	acctttaag	atgggttaatt	cattcaatag	atatttatta	agaacctact	2040

	atgcggcccg	gcatggtggc	tcacacctgt	aatcccagca	ctttgggagg	ccaaggtggg	2100
	tgggtcatct	gaggtcagga	gttcaagacc	agcctggcca	acatggtgaa	accccatctc	2160
	tactaaagat	caaaatttgc	tgagcgtggt	gggtgacacc	tgtatcccag	ctactcgaga	2220
5	ggccaaggca	tgagaatcgc	ttgaacctgg	aggtgaggtt	gcagtgaagct	gagatggcac	2280
	cactgcactc	cggcctaggc	aacgagagca	aaactccaat	acaaacaaac	aaacaaacac	2340
	ctgtgctagg	tcagtctggc	acgtaagatg	aacatcccta	ccaacacaga	gctcaccatc	2400
	tcttatactt	aagtgaaaaa	catgggggaag	gggaaagggg	aatggctgct	tttgatatgt	2460
	tccctgacgc	atatcttgaa	tggagacctc	cctaccaagt	gatgaaagtg	ttgaaaaact	2520
10	taataacaaa	tgcttggttg	gcaagaatgg	gattgaggat	tatcttctct	cagaaaggca	2580
	ttgtgaagga	attgagccag	atctctctcc	ctactgcaaa	accctattgt	agtaaaaaag	2640
	tcttctttac	tatcttaata	aaacagatat	tgtgagattc	acataaaaaa	aaaaaaaaaa	2700
	aaaa						2704
	<210> 2						
15	<211> 1516						
	<212> DNA						
	<213> APEX-2						
	<400> 2						
20	ttcaagttcc	acgttcccta	ctgctaagag	tcttagctta	caaaagatat	tcttgaagc	60
	caagtgtgaa	gttaatcacg	acaaccaaag	gtttgctaac	atagaggaag	agctctcatc	120
	aataggggga	cagaaagtct	cagcgacaag	cttatgaaag	aatggctgtc	tcaagggctc	180
	caacaccoga	ctccgctgtg	cagaggatgg	tctggctctt	tccacttgtc	ttctgcctcg	240
	gctcagggag	tgaagtttca	cagagcagct	cagaccccca	gctaataaat	ggcgttctag	300
25	gagagtctgc	agttcttctc	ctaaagcttc	ctgcagggaa	gatagccaat	atcatcatct	360
	ggaattatga	atgggaagcg	tcacaagtca	ctgccctcgt	tatcaacctc	agtaatcctg	420
	aaagtccaca	aatcatgaac	actgatgtaa	agaagagact	gaacatcacc	cagtcctact	480
	ccctgcaaat	cagcaacctt	accatggcag	acacaggatc	atacactgcg	cagataacca	540
	caaaggactc	tgaagtgatc	accttcaaat	atattctgag	ggtctttgaa	cgattgggta	600
30	acttagaacc	taccaactat	actctcctgc	tagagaatgg	gacctgccag	atacacctgg	660
	cctgtgtttt	gaagaatcaa	agtcaaaactg	tctcagttga	gtggcaagcc	acaggaaaca	720
	tctctttagg	aggaccaaat	gtcactatct	tttgggaccc	gaggaattct	ggtgaccaga	780
	cttacgtctg	cagagccaag	aatgctgtca	gcaatttgct	agtctctgtt	tcgaccacga	840
	gtctctgcaa	aggggttcta	actaatccac	cctggaatgc	agtatgggtt	atgactacaa	900
35	tttcaataat	cagtgcagtc	atactcatct	ttgtgtgctg	gagcatacat	gtttggaaga	960
	gaagaggttc	tcttcctttg	actagccaac	atccagagtc	ctcccagagc	acagatggcc	1020
	caggctctcc	agggaaacct	gtgtatgcac	aagtcactcg	tccaatgcag	gaaatgaaaa	1080
	tcccaaaacc	tatcaaaaat	gactccatga	caatttactc	catagttaat	cattccagag	1140
	aggaaacagt	ggctttaacc	ggctataaacc	aaccatttac	cctgaagggt	aacactttaa	1200
40	tcaactataa	ctcctgaagg	aagagcactg	cagtgaactg	aggaaattaa	acaatgctgt	1260
	caccacagct	ctggcttaga	ttaatgaagt	cagcatctct	ggagattgag	cgctgccatt	1320
	tgcattgttc	aaacgctttc	taggtggtat	ggtgagatgc	cagagggcta	agggccatta	1380
	tagcagggta	gtttgactag	gaatacataa	gatagaaagc	ctagaatcgt	atcattgaaa	1440
45	gggacaatgg	acctaagaga	agtggaataa	aattgtgtca	cacaaaaaaa	aaaaaaaaaa	1500
	aaaaaaaaaa	gcttgt					1516
	<210> 3						
	<211> 1408						
	<212> DNA						
50	<213> APEX-3						
	<400> 3						
	gaattcgaat	tcgggacttt	ccagaaggac	cacagctcct	cccgtgcac	cactcggcct	60
55	gggaggttct	ggattttggc	tgtcgaggga	gtttgcctgc	ctctccagag	aaagatggct	120
	atgaggcccc	tgtggagtct	gcttctctgg	gaagccctac	ttcccattac	agttactggt	180
	gccccagtg	tgagcaaaat	cgggggctcg	gtgctgctgg	tggcagcgcg	tccccctggc	240
	ttccaagtcc	gtgaggctat	ctggcgatct	ctctggcctt	cagaagagct	cctggccacg	300

tttttccgag gctccctgga gactctgtac cattcccgt tccctgggccg agcccagcta 360  
 cacagcaacc tcagcctgga gctcggggccg ctggagtctg gagacagcgg caacttctcc 420  
 gtgttgatgg tggacacaag gggccagccc tggaccaga cccctccagct caaggtgtac 480  
 gatgcagtgc ccagggccgt ggtacaagtg ttcatgtctg tagaaaggga tgctcagccc 540  
 5 tccaagacct gccaggtttt cttgtcctgt tggggcccca acatcagcga aataacctat 600  
 agctggcgac gggagacaac catggacttt ggtatggaac cacacagcct cttcacagac 660  
 ggacaggtag tgagcatttc cctgggacca ggagacagag atgtggccta ttctgcatt 720  
 gtctccaacc ctgtcagctg ggacttggcc acagtacgc cctgggatat ctgtcatcat 780  
 gaggcagcac cagggaaggc ctctacaaa gatgtgctgc tgggtgggtgt gcctgtctcg 840  
 10 ctgctcctga tgctggttac tctcttctct gcctggcact ggtggccctg ctcagggaaa 900  
 aagaaaaagg atgtccatgc tgacagagtg ggtccagaga cagagaaccc ccttgtgcag 960  
 gatctgccat aaaggacaat atgaactgat gcctggacta tcagtaaccc cactgcacag 1020  
 gcacacgatg ctctgggaca taactggtgc ctggaaatca ccatggtcct catatctccc 1080  
 atgggaatcc tgcctgcct cgaaggagca gcctgggcag ccatcacacc acgaggacag 1140  
 15 gaagcaccag cacgtttcac acctccccct tccctctccc atcttctcat atcctggctc 1200  
 ttctctgggc aagatgagcc aagcagaaca ttccatccag gacactggaa gttctccagg 1260  
 atccagatcc atggggacat taatagtcca aggcattccc tccccacca ctattcataa 1320  
 agtattaacc aactggcacc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1380  
 aaaaaaaaaa aaaaagggcg gccgccc 1408

&lt;210&gt; 4

&lt;211&gt; 335

&lt;212&gt; PRT

&lt;213&gt; APEX-1

25

&lt;400&gt; 4

Met Ala Gly Ser Pro Thr Cys Leu Thr Leu Ile Tyr Ile Leu Trp Gln  
 1 5 10 15

30

Leu Thr Gly Ser Ala Ala Ser Gly Pro Val Lys Glu Leu Val Gly Ser  
 20 25 30

Val Gly Gly Ala Val Thr Phe Pro Leu Lys Ser Lys Val Lys Gln Val  
 35 40 45

35

Asp Ser Ile Val Trp Thr Phe Asn Thr Thr Pro Leu Val Thr Ile Gln  
 50 55 60

40

Pro Glu Gly Gly Thr Ile Ile Val Thr Gln Asn Arg Asn Arg Glu Arg  
 65 70 75 80

Val Asp Phe Pro Asp Gly Gly Tyr Ser Leu Lys Leu Ser Lys Leu Lys  
 85 90 95

45

Lys Asn Asp Ser Gly Ile Tyr Tyr Val Gly Ile Tyr Ser Ser Ser Leu  
 100 105 110

Gln Gln Pro Ser Thr Gln Glu Tyr Val Leu His Val Tyr Glu His Leu  
 115 120 125

50

Ser Lys Pro Lys Val Thr Met Gly Leu Gln Ser Asn Lys Asn Gly Thr  
 130 135 140

55

Cys Val Thr Asn Leu Thr Cys Cys Met Glu His Gly Glu Glu Asp Val  
 145 150 155 160

Ile Tyr Thr Trp Lys Ala Leu Gly Gln Ala Ala Asn Glu Ser His Asn

	165						170						175					
Gly Ser Ile Leu Pro Ile Ser Trp Arg Trp Gly Glu Ser Asp Met Thr 180                       185                       190																		
Phe Ile Cys Val Ala Arg Asn Pro Val Ser Arg Asn Phe Ser Ser Pro 195                       200                       205																		
Ile Leu Ala Arg Lys Leu Cys Glu Gly Ala Ala Asp Asp Pro Asp Ser 210                       215                       220																		
Ser Met Val Leu Leu Cys Leu Leu Leu Val Pro Leu Leu Leu Ser Leu 225                                230                                235                                240																		
Phe Val Leu Gly Leu Phe Leu Trp Phe Leu Lys Arg Glu Arg Gln Glu 245                       250                       255																		
Glu Tyr Ile Glu Glu Lys Lys Arg Val Asp Ile Cys Arg Glu Thr Pro 260                       265                       270																		
Asn Ile Cys Pro His Ser Gly Glu Asn Thr Glu Tyr Asp Thr Ile Pro 275                       280                       285																		
His Thr Asn Arg Thr Ile Leu Lys Glu Asp Pro Ala Asn Thr Val Tyr 290                                295                                300																		
Ser Thr Val Glu Ile Pro Lys Lys Met Glu Asn Pro His Ser Leu Leu 305                                310                                315                                320																		
Thr Met Pro Asp Thr Pro Arg Leu Phe Ala Tyr Glu Asn Val Ile 325                       330                       335																		
<210> 5																		
<211> 351																		
<212> PRT																		
<213> APEX-2																		
<400> 5																		
Met Ala Val Ser Arg Ala Pro Thr Pro Asp Ser Ala Cys Gln Arg Met 1                                5                                10                                15																		
Val Trp Leu Phe Pro Leu Val Phe Cys Leu Gly Ser Gly Ser Glu Val 20                       25                       30																		
Ser Gln Ser Ser Ser Asp Pro Gln Leu Met Asn Gly Val Leu Gly Glu 35                                40                                45																		
Ser Ala Val Leu Pro Leu Lys Leu Pro Ala Gly Lys Ile Ala Asn Ile 50                                55                                60																		
Ile Ile Trp Asn Tyr Glu Trp Glu Ala Ser Gln Val Thr Ala Leu Val 65                                70                                75                                80																		
Ile Asn Leu Ser Asn Pro Glu Ser Pro Gln Ile Met Asn Thr Asp Val 85                       90                       95																		

Lys Lys Arg Leu Asn Ile Thr Gln Ser Tyr Ser Leu Gln Ile Ser Asn  
 100 105 110  
 5 Leu Thr Met Ala Asp Thr Gly Ser Tyr Thr Ala Gln Ile Thr Thr Lys  
 115 120 125  
 Asp Ser Glu Val Ile Thr Phe Lys Tyr Ile Leu Arg Val Phe Glu Arg  
 130 135 140  
 10 Leu Gly Asn Leu Glu Thr Thr Asn Tyr Thr Leu Leu Leu Glu Asn Gly  
 145 150 155 160  
 Thr Cys Gln Ile His Leu Ala Cys Val Leu Lys Asn Gln Ser Gln Thr  
 165 170 175  
 15 Val Ser Val Glu Trp Gln Ala Thr Gly Asn Ile Ser Leu Gly Gly Pro  
 180 185 190  
 Asn Val Thr Ile Phe Trp Asp Pro Arg Asn Ser Gly Asp Gln Thr Tyr  
 195 200 205  
 20 Val Cys Arg Ala Lys Asn Ala Val Ser Asn Leu Ser Val Ser Val Ser  
 210 215 220  
 25 Thr Gln Ser Leu Cys Lys Gly Val Leu Thr Asn Pro Pro Trp Asn Ala  
 225 230 235 240  
 Val Trp Phe Met Thr Thr Ile Ser Ile Ile Ser Ala Val Ile Leu Ile  
 245 250 255  
 30 Phe Val Cys Trp Ser Ile His Val Trp Lys Arg Arg Gly Ser Leu Pro  
 260 265 270  
 Leu Thr Ser Gln His Pro Glu Ser Ser Gln Ser Thr Asp Gly Pro Gly  
 275 280 285  
 35 Ser Pro Gly Asn Thr Val Tyr Ala Gln Val Thr Arg Pro Met Gln Glu  
 290 295 300  
 40 Met Lys Ile Pro Lys Pro Ile Lys Asn Asp Ser Met Thr Ile Tyr Ser  
 305 310 315 320  
 Ile Val Asn His Ser Arg Glu Glu Thr Val Ala Leu Thr Gly Tyr Asn  
 325 330 335  
 45 Gln Pro Ile Thr Leu Lys Val Asn Thr Leu Ile Asn Tyr Asn Ser  
 340 345 350  
 50 <210> 6  
 <211> 285  
 <212> PRT  
 <213> APEX-3  
 55 <400> 6  
 Met Val Met Arg Pro Leu Trp Ser Leu Leu Leu Trp Glu Ala Leu Leu  
 1 5 10 15



Pro Ile Thr Val Thr Gly Ala Gln Val Leu Ser Lys Val Gly Gly Ser  
                     20                    25                    30

5 Val Leu Leu Val Ala Ala Arg Pro Pro Gly Phe Gln Val Arg Glu Ala  
                     35                    40                    45

Ile Trp Arg Ser Leu Trp Pro Ser Glu Glu Leu Leu Ala Thr Phe Phe  
                     50                    55                    60

10 Arg Gly Ser Leu Glu Thr Leu Tyr His Ser Arg Phe Leu Gly Arg Ala  
                     65                    70                    75                    80

15 Gln Leu His Ser Asn Leu Ser Leu Glu Leu Gly Pro Leu Glu Ser Gly  
                     85                    90                    95

Asp Ser Gly Asn Phe Ser Val Leu Met Val Asp Thr Arg Gly Gln Pro  
                     100                    105                    110

20 Trp Thr Gln Thr Leu Gln Leu Lys Val Tyr Asp Ala Val Pro Arg Pro  
                     115                    120                    125

Val Val Gln Val Phe Ile Ala Val Glu Arg Asp Ala Gln Pro Ser Lys  
                     130                    135                    140

25 Thr Cys Gln Val Phe Leu Ser Cys Trp Ala Pro Asn Ile Ser Glu Ile  
                     145                    150                    155                    160

30 Thr Tyr Ser Trp Arg Arg Glu Thr Thr Met Asp Phe Gly Met Glu Pro  
                     165                    170                    175

His Ser Leu Phe Thr Asp Gly Gln Val Leu Ser Ile Ser Leu Gly Pro  
                     180                    185                    190

35 Gly Asp Arg Asp Val Ala Tyr Ser Cys Ile Val Ser Asn Pro Val Ser  
                     195                    200                    205

Trp Asp Leu Ala Thr Val Thr Pro Trp Asp Ser Cys His His Glu Ala  
                     210                    215                    220

40 Ala Pro Gly Lys Ala Ser Tyr Lys Asp Val Leu Leu Val Val Val Pro  
                     225                    230                    235                    240

45 Val Ser Leu Leu Leu Met Leu Val Thr Leu Phe Ser Ala Trp His Trp  
                     245                    250                    255

Cys Pro Cys Ser Gly Lys Lys Lys Lys Asp Val His Ala Asp Arg Val  
                     260                    265                    270

50 Gly Pro Glu Thr Glu Asn Pro Leu Val Gln Asp Leu Pro  
                     275                    280                    285

55 <210> 7  
     <211> 19  
     <212> DNA  
     <213> JNF1 primer

<400> 7  
cagagtacga cacaatccc 19

5 <210> 8  
<211> 20  
<212> DNA  
<213> JNF2 primer

10 <400> 8  
actccactgt ggaaataccg 20

<210> 9  
<211> 52

15 <212> DNA  
<213> JNF3 primer

<400> 9  
ccagtgcgca gagtgcgag gactcgagct caagcttttt tttttttttt tt 52

20 <210> 10  
<211> 18  
<212> DNA  
<213> JNF4 primer

25 <400> 10  
gaggactcga gctcaagc 18

<210> 11  
<211> 18

30 <212> DNA  
<213> JNF5 primer

<400> 11

35 ccagtgcgca gagtgcg 18

<210> 12  
<211> 20  
<212> DNA

40 <213> JNF6 primer

<400> 12  
atcctttggc agctcacagg 20

45 <210> 13  
<211> 19  
<212> DNA  
<213> JNF7 primer

50 <400> 13  
cttcacagag cttcctggc 19

<210> 14  
<211> 20

55 <212> DNA  
<213> JNF12 primer

	<400> 14	
	gagtcttgct accaggaggg	20
5	<210> 15	
	<211> 20	
	<212> DNA	
	<213> JNF13 primer	
10	<400> 15	
	gacacagaag tgtgcatggc	20
	<210> 16	
	<211> 20	
	<212> DNA	
15	<213> JNF14 primer	
	<400> 16	
	tggtcacac ctgtaatccc	20
20	<210> 17	
	<211> 20	
	<212> DNA	
	<213> JNF15 primer	
25	<400> 17	
	catctcagct cactgcaacc	20
	<210> 18	
	<211> 20	
30	<212> DNA	
	<213> JNF16 primer	
	<400> 18	
35	gactcggctct ctttattggg	20
	<210> 19	
	<211> 20	
	<212> DNA	
40	<213> JNF17 primer	
	<400> 19	
	aagctcagca tagtgctggg	20
	<210> 20	
45	<211> 20	
	<212> DNA	
	<213> JNF18 primer	
	<400> 20	
50	gatttctcag cagtggatgg	
	<210> 21	
	<211> 32	
	<212> DNA	
55	<213> Llewellyn4 primer	
	<400> 21	

	cccaagcttc cagagagcaa tatggctggt cc	32
	<210> 22	
	<211> 20	
5	<212> DNA	
	<213> JNF19 primer	
	<400> 22	
10	acctgccaga tacacctggc	20
	<210> 23	
	<211> 20	
	<212> DNA	
15	<213> JNF20 primer	
	<400> 23	
	agacttacgt ctgcagagcc	20
	<210> 24	
20	<211> 20	
	<212> DNA	
	<213> JNF21 primer	
	<400> 24	
25	gctggagcat acatgtttgg	20
	<210> 25	
	<211> 20	
	<212> DNA	
30	<213> JNF22 primer	
	<400> 25	
	ttaaccttca gggtaatggg	20
35	<210> 26	
	<211> 20	
	<212> DNA	
	<213> JNF23 primer	
40	<400> 26	
	gaacaatgca aatggcagcg	20
	<210> 27	
45	<211> 20	
	<212> DNA	
	<213> JNF33 primer	
	<400> 27	
50	acaggacaag aaaacctggc	20
	<210> 28	
	<211> 21	
	<212> DNA	
55	<213> JNF34 primer	
	<400> 28	
	cgaaataacc tatagctggc g	21

<210> 29  
<211> 20  
<212> DNA  
5 <213> JNF35 primer  
  
<400> 29  
tctgcattg tctccaaccc 20  
  
10 <210> 30  
<211> 19  
<212> DNA  
<213> JNF36 primer  
  
15 <400> 30  
ggcagatcct gcacaagg 19  
  
<210> 31  
<211> 20  
20 <212> DNA  
<213> JNF37 primer  
  
<400> 31  
atcttgccca gagaagagcc 20  
25  
<210> 32  
<211> 20  
<212> DNA  
<213> JNF38 primer  
30  
<400> 32  
gaagctgatg ctggcatggg 20  
  
<210> 33  
35 <211> 20  
<212> DNA  
<213> JNF39 primer  
  
<400> 33  
40 catatctccc atgggaatcc 20  
  
<210> 34  
<211> 21  
<212> DNA  
45 <213> JNF40 primer  
  
<400> 34  
ctggcctaag gactttcagg t 21  
50  
  
55

What is claimed is:

1. An isolated nucleic acid molecule encoding APEX-1.
- 5      2. The isolated nucleic acid molecule of claim 1, wherein the molecule begins with a guanine (g) at position 1 and ends with an adenine (a) at position 2704 as shown in SEQ ID NO. 1.
- 10      3. The isolated nucleic acid molecule of claim 1, wherein APEX-1 has an amino acid sequence shown in SEQ ID NO. 4.
- 15      4. The isolated nucleic acid molecule of claim 3, wherein the amino acid sequence is encoded by a nucleotide sequence beginning with adenine (a) at position 42 and ending with guanine (g) at position 1049 as shown in SEQ ID NO. 1.
- 20      5. The isolated nucleic acid molecule of claim 1, wherein APEX-1 has an extracellular domain encoded by nucleotide sequences beginning with thymine (t) at position 108 and ending with cytosine (c) at position 716 as shown in SEQ ID NO. 1.
- 25      6. An isolated nucleic acid molecule encoding APEX-2.
- 30      7. The isolated nucleic acid molecule of claim 6, wherein the molecule begins with thymine (t) at position 1 and ends with thymine (t) at position 1516 as shown in SEQ ID NO.2, or a fragment thereof.
8. The isolated nucleic acid molecule of claim 6, wherein APEX-2 has an amino acid sequence shown in SEQ ID NO. 5.
9. The isolated nucleic acid molecule of claim 8, wherein the amino acid sequence is encoded by a nucleotide sequence beginning with adenine (a) at position 162 and ending with adenine at position 1217 as shown in SEQ ID NO. 2.

10. The isolated nucleic acid molecule of claim 6, wherein APEX-2 has an  
extracellular domain encoded by nucleotide sequences beginning at adenine (a) at  
position 249 and ending with guanine (g) at position 875 as shown in SEQ ID  
5 NO. 2.
11. An isolated nucleic acid molecule encoding APEX-3.
12. The isolated nucleic acid molecule of claim 11, wherein the molecule begins with  
10 guanine (g) at position 1 and ends with guanine (g) at position 1408 as shown in  
SEQ ID. NO. 3.
13. The isolated nucleic acid molecule of claim 11, wherein APEX-3 has an amino  
acid sequence shown in SEQ ID NO. 6.
- 15 14. The isolated nucleic acid molecule of claim 13, wherein the amino acid sequence  
is encoded by a nucleotide sequence beginning with adenine (a) at position 115  
and ending with adenine at position 972 as shown in SEQ ID NO. 3.
- 20 15. An isolated polynucleotide variant having at least 70% polynucleotide sequence  
identity to the polynucleotide of claim 1, 6, or 11.
16. An isolated polynucleotide which hybridizes under stringent conditions to the  
complement of polynucleotide of claim 1, 6, or 11.
- 25 17. An isolated nucleic acid molecule comprising a nucleotide sequence which is  
complementary to the isolated nucleic acid molecule of claim 1, 6, or 11.
18. The isolated nucleic acid molecule of claim 1, 6, or 11 which is DNA or RNA.
- 30 19. The isolated nucleic acid molecule of claim 18, wherein the DNA is cDNA.


20. The isolated nucleic acid of claim 18, wherein the RNA is mRNA.
21. The isolated nucleic acid molecule of claim 1, 6, or 11 which is labeled with a  
5 detectable marker.
22. The nucleic acid molecule of claim 21, wherein the detectable marker is selected  
from the group consisting of a radioisotope, a fluorescent compound, a  
bioluminescent compound, a chemiluminescent compound, a metal chelator and  
10 an enzyme.
23. A vector comprising the nucleotide sequence of claim 1, 6, or 11.
24. A host vector system comprising the vector of claim 23 in a suitable host cell.  
15
25. The host vector system of claim 24, wherein the suitable host is a bacterial cell.
26. The host vector system of claim 24, wherein the suitable host is an eukaryotic  
cell.  
20
27. An isolated protein designated APEX-1 or APEX-2, comprising an extracellular  
domain having at least one Ig-like structure and at least one N-glycosylation site,  
a transmembrane domain, and a cytoplasmic domain having at least one SH2-  
binding motif.  
25
28. The isolated protein designated APEX-1 of claim 27, having the amino acid  
sequence beginning at Met at position 1 and ending at Ile at position 335 as  
shown in SEQ. ID. No. 4, or fragments thereof, the protein or the fragments  
having APEX activity.  
30



29. The isolated protein designated APEX-2 of claim 27, having the amino acid sequence beginning with Met at position 1 and ending at Ser at position 351 as shown in SEQ. ID. NO. 5, or fragments thereof, the protein or the fragments having APEX activity.
- 5 30. An isolated protein designated APEX-3 consisting of the amino acid sequence beginning with Met at position 1 and ending at Pro at position 285 as shown in SEQ. ID. NO. 6.
- 10 31. An antibody which recognizes and binds to the isolated protein of claim 27 or 30, or a fragment thereof having APEX activity.
32. A Fab', F(ab)2', or Fv fragment of the antibody of claim 31.
- 15 33. The antibody of claim 31, which is a monoclonal antibody.
34. The antibody of claim 33, which is 40-A10-G3 (ATCC Accession No.).
35. The antibody of claim 33, which is 66-H2-E5 (ATCC Accession No.).
- 20 36. The antibody of claim 33, which is 68-F12-G6 (ATCC Accession No.).
37. The antibody of claim 33, which is 71-E9-F10 (ATCC Accession No.).
- 25 38. The antibody of claim 31, which is a polyclonal antibody.
39. The antibody of claim 31, wherein the antibody is a chimeric antibody having a murine antigen-binding site and a humanized region that regulates effector functions.
- 30 40. The antibody of claim 31 which is labeled with a detectable marker.

41. The antibody of claim 40, wherein the detectable marker is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator and an enzyme.
- 5      42. A method of producing an APEX protein comprising:
- a) culturing the host-vector system of claim 24 under suitable conditions so as to produce the APEX protein; and
  - b) recovering the APEX protein so produced.
- 10      43. An APEX protein produced by the method of claim 42.
44. A soluble APEX protein having a first amino acid sequence corresponding to an extracellular domain of an APEX protein and a second amino acid sequence corresponding to a moiety that alters the solubility of said APEX protein.
- 15      45. The soluble APEX protein of claim 44, wherein said moiety is an immunoglobulin constant region.
46. The soluble APEX protein of claim 44, wherein the APEX protein is APEX-1, APEX-2, or APEX-3.
- 20      47. A method for identifying a molecule in a sample which specifically binds an APEX protein, the method comprising:
- 25      (a) contacting the APEX protein with the sample under suitable conditions so as to obtain a complex having the APEX protein and the molecule;
  - (b) recovering the complex; and
  - 30      (c) separating the APEX protein from the molecule in the complex and identifying the molecule so separated.

48. A method of of claim 47, wherein the sample is a tissue, e.g., brain, bone marrow,  
heart, kidney, liver, lung, lymph node, pancreas, placenta, skeletal muscle,  
thymus.
- 5
49. A method of claim 47, wherein the sample is a biological fluid, e.g., blood, urine,  
plasma, serum.
50. A nucleic acid molecule having a nucleotide sequence selected from a group  
consisting of SEQ ID NO: 7 to SEQ ID NO: 42.
- 10
51. A pharmaceutical composition comprising the APEX protein of claim 28, 29, or  
30, and an acceptable carrier.
52. A pharmaceutical composition comprising an antibody or a antibody fragment  
thereof, that recognizes an APEX protein, and an acceptable carrier.
- 15
- 20
- 25



• = potential N-linked glycosylation sites

FIGURE 1

GGAAGTGGCTTCATTTTCAGTGGCTGACTTCCAGAGAGCAAT 41  
 ATGGCTGGTTCCCCAACATGCCCTCACCTCATCTATATCCTTTGGCAGCTCACAGGGTCA 101  
M A G S P T C L T L I Y I L W Q L T G S 20  
 GCAGCCTCTGGACCCGTGAAAGAGCTGGTCGGTTCGGTTGGTGGGGCCGTGACTTTCCCC 161  
A A S G P V K E L V G S V G G A V T F P 40  
 CTGAAGTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAACCCCTCTT 221  
 L K S K V K Q V D S I V W T F N T T P L 60  
 GTCACCATACAGCCAGAAGGGGGCACTATCATAGTGACCCAAATCGTAATAGGGAGAGA 281  
 V T I Q P E G G T I I V T Q N R N R E R 80  
 GTAGACTTCCAGATGGAGGCTACTCCCTGAAGCTCAGCAAATGAAGAAGATGACTCA 341  
 V D F P D G G Y S L K L S K L K K N D S 100  
 GGGATCTACTATGTGGGATATACAGCTCATCACTCCAGCAGCCCTCCACCCAGGATAC 401  
 G I Y Y V G I Y S S S L Q Q P S T Q E Y 120  
 GTGCTGCATGTCTACGAGCACCTGTCAAAGCCTAAAGTCACCATGGGTCTGCAGAGCAAT 461  
 V L H V Y E H L S K P K V T M G L Q S N 140  
 AAGAATGGCACCTGTGTGACCAATCTGACATGCTGCATGGAACATGGGAAGAGGATGTG 521  
 K N G T C V T N L T C C M E H G E E D V 160  
 ATTTATACCTGGAAGCCCTGGGGCAAGCAGCCAATGAGTCCCATTAATGGGTCCATCCTC 581  
 I Y T W K A L G Q A A N E S H N G S I L 180  
 CCCATCTCCTGGAGATGGGGAGAAAGTGATGACCTTCATCTGCGTTGCCAGGAACCT 641  
 P I S W R W G E S D M T F I C V A R N P 200  
 GTCAGCAGAACTTCTCAAGCCCCATCCTTGCCAGGAAGCTCTGTGAAGGTGCTGTGAT 701  
 V S R N E S S P I L A R K L C E G A A D 220  
 GACCCAGATTCTCCATGGTCTCTCTGTCTCTCTGTTGGTGGCCCTCTGCTCAGTCTC 761  
 D P D S S M V L L C L L L V P L L L S L 240  
TTGTACTGGGGCTATTCTTTGGTTTCTGAAGAGAGAGACAAGAAGATACATTGAA 821  
F V L G L F L W F L K R E R Q E E Y I E 260  
 GAGAAGAAGAGAGTGACATTTGTGGGAACTCCTAACATATGCCCCCATTTCTGGAGAG 881  
 E K K R V D I C R E T P N I C P H S G E 280  
 AACACAGAGTACGACACAATCCCTCACACTAATAGAACAATCCTAAAGGAAGATCCAGCA 941  
 N T E Y D T I P H T N R T I L K E D P A 300  
 AATACGGTTTACTCCACTGTGGAATACCGAAAAAGATGGAAAATCCCCACTCACTGCTC 1001  
 N T V Y S T V E I P K K M E N P H S L L 320  
 ACGATGCCAGACACCAAGGCTATTTGCCTATGAGAATGTTATCTAGACAGCAGTGCAC 1061  
 T M P D T P R L F A Y E N V I \* 335  
 TCCCTAAGTCTCTGCTCAAAAAAACAATTCTCGGCCCAAGAAAAACAATCAGAAGA 1121  
 ATTCAGTGATTGACTAGAAACATCAAGGAAGAATGAAGAAGTTGACTTTTTCAGGA 1181  
 TAAATTATCTCTGATGCTTCTTTAGATTAAAGAGTTCGTAATTCATCCACTGCTGAGAA 1241  
 ATCTCCTCAACCCAGAAGGTTAATCACTTCATCCCAAAATGGGATTGTGAATGTCAG 1301  
 CAAACCATAAAAAAGTCTTAGAAGTATTCCTATAGAAATGTAAATGCAAGGTCACACA 1361  
 TATTAATGACAGCCTGTGTATTAATGATGGCTCCAGGTCAGTGTCTGGAGTTTCATTCC 1421  
 ATCCAGGGCTTGGATGTCAGGATTATACCAAGAGTCTTGCTACCAGGAGGGCAAGAAGA 1481  
 CCAAAACAGACAGCAAGTCCAGCAGAAGCAGATGCACCTGACAAAAATGGATGTATTA 1541  
 TTGGCTCTATAAACTATGTGCCAGCACTATGCTGAGCTTACACTAATTGGTCAGACGTG 1601  
 CTGCTGCCCTCATGAATTTGGCTCCAAATGAATGAATACTTTTCATGAGCAGTTGTAGC 1661  
 AGGCCTGACCACAGATTTCCAGAGGGCCAGGTGTGGATCCACAGGACTTGAAGGTCAAAG 1721  
 TTCACAAAGATGAAGAATCAGGGTAGCTGACCATGTTTGGCAGATACTATAATGGAGACA 1781  
 CAGAAGTGTGCATGGCCCAAGGACAAGGACCTCCAGCCAGGCTTCATTTATGCACTTGTG 1841  
 CTGCAAAAGAAAAGTCTAGGTTTTAAGGCTGTGCCAGAACCCTCCCAATAAAGAGACCG 1901  
 AGTCTGAAGTCACATTGTAAATCTAGTGTAGGAGACTTGGAGTCAGGCACTGAGACTGGT 1961  
 GGGGCACGGGGGGCAGTGGGTACTTGTAAACCTTTAAAGATGGTTAATTCATTCAATAGA 2021  
 TATTTATTAAGAACCTACTATGCGGCCCGGCATGGTGGCTCACACCTGTAAATCCAGCAC 2081  
 TTTGGAGGCCAAGGTGGTGGTCTATCTGAGGTGAGGAGTTCAAGACCAGCCTGGCCAA 2141  
 CATGGTGAACCCCATCTCTACTAAAGATCAAAATTTGCTGAGCGTGGTGGTGCACCT 2201

FIGURE 2

GTATCCCAGCTACTCGAGAGGCCAAGGCATGAGAATCGCTTGAACCTGGAGGTGAGGTTG 2261  
CAGTGAGCTGAGATGGCACCCTGCACTCCGGCCTAGGCAACGAGAGCAAACTCCAATA 2321  
CAAACAAACAAACAAACACCTGTGCTAGGTCAGTCTGGCACGTAAGATGAACATCCCTAC 2381  
CAACACAGAGCTCACCATCTCTTATACTTAAGTGAAAAACATGGGGAAGGGGAAAGGGGA 2441  
ATGGCTGCTTTTGATATGTTCCCTGACGCATATCTTGAATGGAGACCTCCCTACCAAGTG 2501  
ATGAAAGTGTGAAAACTTAATAACAAATGCTTGTGGGCAAGAATGGGATTGAGGATT 2561  
ATCTTCTCTCAGAAAGGCATTGTGAAGGAATTGAGCCAGATCTCTCTCCCTACTGCAAAA 2621  
CCCTATTGTAGTAAAAAAGTCTTCTTACTATCTTAATAAAACAGATATTGTGAGATTCA 2681  
CATAAAAAAAAAAAAAAAAAAAAA

FIGURE 2 (continued)

CCATCCTAATAAGACTCACTATAGGGCTCGAGCGGCCGCCCAGGTTCACAGTTCCA  
1 -----+-----+-----+-----+-----+-----+-----+  
  
CGTTCCTACTGCTAAGAGTCTTAGCTTACAAAAGATATTCTTGTAAGCCAAGTGTGAAG  
61 -----+-----+-----+-----+-----+-----+-----+  
  
TTAATCACGACAACCAAAGGTTTGCTAACATAGAGGAAGAGCTCTCATCAATAGGGGAAC  
121 -----+-----+-----+-----+-----+-----+-----+  
  
AGAAAGTCTCAGCGACAAGCTTATGAAAGAATGGCTGTCTCAAGGGCTCCAACACCCGAC  
181 -----+-----+-----+-----+-----+-----+-----+  
M A V S R A P T P D  
  
TCCGCCTGTGAGAGGATGGTCTGGCTCTTTCCACTTGTCTTCTGCCTCGGCTCAGGGAGT  
241 -----+-----+-----+-----+-----+-----+-----+  
S A C Q R M V W L F P L V F C L G S G S  
  
GAAGTTTCACAGAGCAGCTCAGACCCCCAGCTAATGAATGGCGTTCTAGGAGAGTCTGCA  
301 -----+-----+-----+-----+-----+-----+-----+  
E V S Q S S S D P Q L M N G V L G E S A  
  
GTTCTTCCTCTAAAGCTTCCTGCAGGGAAGATAGCCAATATCATCATCTGGAATTATGAA  
361 -----+-----+-----+-----+-----+-----+-----+  
V L P L K L P A G K I A N I I I W N Y E  
  
TGGAAGCGTCACAAGTCACTGCCCTCGTTATCAACCTAAGTAATCCTGAAAGTCCACAA  
421 -----+-----+-----+-----+-----+-----+-----+  
W E A S Q V T A L V I N L S N P E S P Q  
  
ATCATGAACACTGATGTAAAGAAGAGACTGAACATCACCCAGTCTACTCCCTGCAAATC  
481 -----+-----+-----+-----+-----+-----+-----+  
I M N T D V K K R L N I T Q S Y S L Q I  
  
AGCAACCTTACCATGGCAGACACAGGATCATACACTGCGCAGATAACCACAAAGGACTCT  
541 -----+-----+-----+-----+-----+-----+-----+  
S N L T M A D T G S Y T A Q I T T K D S  
  
GAAGTGATCACCTTCAAATATATTCTGAGGGTCTTTGAACGATTGGGTAACTTAGAAACT  
601 -----+-----+-----+-----+-----+-----+-----+  
E V I T F K Y I L R V F E R L G N L E T

FIGURE 3

ACCAACTATACTCTCCTGCTAGAGAATGGGACCTGCCAGATACACCTGGCCTGTGTTTTG  
661 -----+-----+-----+-----+-----+  
T N Y T L L L E N G T C Q I H L A C V L

AAGAATCAAAGTCAAAGTGTCTCAGTTGAGTGGCAAGCCACAGGAAACATCTCTTTAGGA  
721 -----+-----+-----+-----+-----+  
K N Q S Q T V S V E W Q A T G N I S L G

GGACCAAATGTCACCTATCTTTTGGGACCCGAGGAATTCTGGTGACCAGACTTACGTCTGC  
781 -----+-----+-----+-----+-----+  
G P N V T I F W D P R N S G D Q T Y V C

AGAGCCAAGAATGCTGTCAGCAATTTGTCTCAGTCTCTGTTTCGACCCAGAGTCTCTGCAAA  
841 -----+-----+-----+-----+-----+  
R A K N A V S N L S V S V S T Q S L C K

GGGGTTCTAACTAATCCACCCTGGAATGCAGTATGGTTTATGACTACAATTTCAATAATC  
901 -----+-----+-----+-----+-----+  
G V L T N P P W N A V W F M T T I S I I

AGTGCAGTCATACTCATCTTTGTGTGCTGGAGCATACATGTTTGAAGAGAAGAGGTTCT  
961 -----+-----+-----+-----+-----+  
S A V I L I F V C W S I H V W K R R G S

CTTCCTTTGACTAGCCAACATCCAGAGTCTCCAGAGCACAGATGGCCCAGGCTCTCCA  
1021 -----+-----+-----+-----+-----+  
L P L T S Q H P E S S Q S T D G P G S P

GGGAACACTGTGTATGCACAAGTCACTCGTCCAATGCAGGAAATGAAAATCCCAAAACCT  
1081 -----+-----+-----+-----+-----+  
G N T V Y A Q V T R P M Q E M K I P K P

ATCAAAAATGACTCCATGACAATTTACTCCATAGTTAATCATTCCAGAGAGGAAACAGTG  
1141 -----+-----+-----+-----+-----+  
I K N D S M T I Y S I V N H S R E E T V

GCTTTAACCGGCTATAACCAACCCATTACCTGAAGGTAAACACTTTAATCAACTATAAC  
1201 -----+-----+-----+-----+-----+  
A L T G Y N Q P I T L K V N T L I N Y N

TCCTGAAGGAAGAGCACTGCAGTGACTTGAGGAAATTAAACAATGCTGTCACCACAGCTC  
1261 -----+-----+-----+-----+-----+  
S \*

FIGURE 3 (continued)



1321 TGGCTTAGATTAATGAAGTCAGCATCTCTGGAGATTGAGCGCTGCCATTTGCATTGTTCA  
-----+-----+-----+-----+-----+-----+-----+  
1381 AACGCTTTCTAGGTGGTATGGTGAGATGCCAGAGGGCTAAGGGCCATTATAGCAGGGTAG  
-----+-----+-----+-----+-----+-----+-----+  
1441 TTGACTAGGAATACATAAGATAGAAAGCCTAGAATCGTATCATTGAAAGGGACAATGGA  
-----+-----+-----+-----+-----+-----+-----+  
1501 CCTAAGAGAAGTGAATAAAATTGTGTCACACAAAAAAAAAAAAAAAAAAAAAAAAAAG  
-----+-----+-----+-----+-----+-----+-----+  
CTTGT  
1561 ----- 1565

**FIGURE 3 (continued)**

Apex-3 nucleotide with translation

```
GAATTGGAATTCTGGGACTTTCCAGAAGGACCACAGCTCCTCCCGTGCATCCACTCGGCCT
1  -----+-----+-----+-----+-----+-----+
GGGAGGTTCTGGATTTTGGCTGTCGAGGGAGTTTGCTGCCTCTCCAGAGAAAGATGGTC
61  -----+-----+-----+-----+-----+-----+
                                         M  V
ATGAGGCCCTGTGGAGTCTGCTTCTCTGGAAGCCCTACTTCCCATTACAGTTACTGGT
121 -----+-----+-----+-----+-----+-----+
M  R  P  L  W  S  L  L  L  W  E  A  L  L  P  I  T  V  T  G
GCCCAAGTGCTGAGCAAAGTCGGGGGCTCGGTGCTGCTGGTGGCAGCGCGTCCCCCTGGC
181 -----+-----+-----+-----+-----+-----+
A  Q  V  L  S  K  V  G  G  S  V  L  L  V  A  A  R  P  P  G
TTCCAAGTCCGTGAGGCTATCTGGCGATCTCTCTGGCCTTCAGAAGAGCTCCTGGCCACG
241 -----+-----+-----+-----+-----+-----+
F  Q  V  R  E  A  I  W  R  S  L  W  P  S  E  E  L  L  A  T
TTTTTCCGAGGCTCCCTGGAGACTCTGTACCATTCCCGCTTCCTGGGCCGAGCCCAGCTA
301 -----+-----+-----+-----+-----+-----+
F  F  R  G  S  L  E  T  L  Y  H  S  R  F  L  G  R  A  Q  L
CACAGCAACCTCAGCCTGGAGCTCGGGCCGCTGGAGTCTGGAGACAGCGCAACTTCTCC
361 -----+-----+-----+-----+-----+-----+
H  S  N  L  S  L  E  L  G  P  L  E  S  G  D  S  G  N  F  S
GTGTTGATGGTGGACACAAGGGGCCAGCCCTGGACCCAGACCCTCCAGCTCAAGGTGTAC
421 -----+-----+-----+-----+-----+-----+
V  L  M  V  D  T  R  G  Q  P  W  T  Q  T  L  Q  L  K  V  Y
GATGCAGTGCCCAGGCCCGTGGTACAAGTGTTTCATTGCTGTAGAAAGGGATGCTCAGCCC
481 -----+-----+-----+-----+-----+-----+
D  A  V  P  R  P  V  V  Q  V  F  I  A  V  E  R  D  A  Q  P
TCCAAGACCTGCCAGGTTTCTTGTCCTGTTGGGCCCCCAACATCAGCGAAATAACCTAT
541 -----+-----+-----+-----+-----+-----+
S  K  T  C  Q  V  F  L  S  C  W  A  P  N  I  S  E  I  T  Y
```

FIGURE 4

AGCTGGCGACGGGAGACAACCATGGACTTTGGTATGGAACCACACAGCCTCTTCACAGAC  
601 -----+-----+-----+-----+-----+-----+  
S W R R E T T M D F G M E P H S L F T D

GGACAGGTGCTGAGCATTTCCCTGGGACCAGGAGACAGAGATGTGGCCTATTCCTGCATT  
661 -----+-----+-----+-----+-----+-----+  
G Q V L S I S L G P G D R D V A Y S C I

GTCTCCAACCCTGTCAGCTGGGACTTGGCCACAGTCACGCCCTGGGATAGCTGTCATCAT  
721 -----+-----+-----+-----+-----+-----+  
V S N P V S W D L A T V T P W D S C H H

GAGGCAGCACCCAGGAAGGCCTCCTACAAAGATGTGCTGCTGGTGGTGGTGCCTGTCTCG  
781 -----+-----+-----+-----+-----+-----+  
E A A P G K A S Y K D V L L V V V P V S

CTGCTCCTGATGCTGGTTACTCTCTTCTCTGCCTGGCACTGGTGGCCCTGCTCAGGGAAA  
841 -----+-----+-----+-----+-----+-----+  
L L L M L V T L F S A W H W C P C S G K

AAGAAAAAGGATGTCCATGCTGACAGAGTGGGTCCAGAGACAGAGAACCCCTTGTGCAG  
901 -----+-----+-----+-----+-----+-----+  
K K K D V H A D R V G P E T E N P L V Q

GATCTGCCATAAAGGACAATATGAACTGATGCCTGGACTATCAGTAACCCCACTGCACAG  
961 -----+-----+-----+-----+-----+-----+  
D L P \*

GCACACGATGCTCTGGGACATAACTGGTGCCTGGAAATCACCATGGTCCTCATATCTCCC  
1021 -----+-----+-----+-----+-----+-----+  
ATGGGAATCCTGTCTGCTCGAAGGAGCAGCCTGGGCAGCCATCACACCACGAGGACAG  
1081 -----+-----+-----+-----+-----+-----+  
GAAGCACCAGCACGTTTCACACCTCCCCCTTCCCTCTCCCATCTTCTCATATCCTGGCTC  
1141 -----+-----+-----+-----+-----+-----+  
TTCTCTGGGCAAGATGAGCCAAGCAGAACATTCCATCCAGGACACTGGAAGTTCTCCAGG  
1201 -----+-----+-----+-----+-----+-----+  
-----+-----+-----+-----+-----+-----+

FIGURE 4 (continued)

1261 ATCCAGATCCATGGGGACATTAATAGTCCAAGGCATTCCCTCCCCCACCCTATTCATAA  
-----+-----+-----+-----+-----+-----+-----+  
1321 AGTATTAACCAACTGGCACCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
-----+-----+-----+-----+-----+-----+-----+  
1381 AAAAAAAAAAAAAAGGGCGGCCGCCCG 1408

**FIGURE 4 (continued)**

M A G S P T C L T L I Y I L W Q L T G S  
A A S G P V K E L V G S V G G A V T F P  
L K S K V K Q V D S I V W T F N T T P L  
V T I Q P E G G T I I V T Q N R N R E R  
V D F P D G G Y S L K L S K L K K N D S  
G I Y Y V G I Y S S S L Q Q P S T Q E Y  
V L H V Y E H L S K P K V T M G L Q S N  
K N G T C V T N L T C C M E H G E E D V  
I Y T W K A L G Q A A N E S H N G S I L  
P I S W R W G E S D M T F I C V A R N P  
V S R N F S S P I L A R K L C E G A A D  
D P D S S M V L L C L L V P L L S L  
F V L G L F L W F L K R E R Q E E Y I E  
E K K R V D I C R E T P N I C P H S G E  
N T E Y D T I P H T N R T I L K E D P A  
N T V Y S T V E I P K K M E N P H S L  
T M P D T P R L F A Y E N V I \*

FIGURE 5

M A V S R A P T P D S A C Q R M V W L F P L V F C L G  
S G S E V S Q S S S D P Q L M N G V L G E S A V L P L  
K L P A G K I A N I I W N Y E W E A S Q V T A L V I  
N L S N P E S P Q I M N T D V K K R L N I T Q S Y S L  
Q I S N L R V F E R L G S N L E T T N Y T L L E N G T C  
K Y I L R V F E R L G S N L E T T N Y T L L E N G T C  
Q I H L A C V L K N Q S Q T V S V E W Q A T G N I S L  
G G P N V T I F W D P R N S G D Q T Y V C R A K N A V  
S N L S V S V S T Q S L C K G V L T N P P W N A V W F  
M T T I S I S A V I L I F V C W S I H V W K R R G S  
L P L T S Q H P E S S Q S T D G P G S M T I Y N S  
V T R P M Q E M K I P K P I K N D S M T I Y N S  
S R E E T V A L T G Y N Q P I T L K V N T L I N Y N S  
\*

FIGURE 6

M V M R P L W S L L L W E A L L P I T V T G  
A Q V L S K V G G S V L L V A L A R P P G F Q  
V R E A I W R S L W P S E E L L A T F F R G  
S L E T L Y H S R F L G R A Q L H S N L S L  
E L G P L E S G D S G N F S V L M V D T R G  
Q P W T Q T L Q L K V Y D A V P R P V V Q V  
F I A V E R D A Q P S K T C Q V F L S C W A  
P N I S E I T Y S W R R E T T M D F G M E P  
H S L F T D G Q V L S I S L G P G D R D V A  
Y S C I V S N P V S W D L A T V T P W D S C  
H H E A A P G K A S Y K D V L L V V V P V S  
L L L M L V T L F S A W H W C P C S G K K K  
K D V H A D R V G P E T E N P L V Q D L P \*

FIGURE 7

A



B




FIGURE 8



*Tissue Distribution of Apex1 Expression*




FIGURE 9

**Peptides in APEX-1Ig**

**1 MAGSPTCLTL IYILWQLTGS AASGPVKELV GSVGGAVTFP LKSKVKQVDS**  
51 IVWTFNTTPL VTIQPEGGTI IVTQNRNRER VDFPDGGYSL KLSKLKKNDS  
101 GIYYVVGIISS SLOQPSTQEY VLVHVEHLSK PKVTMGLQSN KNGTCVTNLT  
151 CCMEHGEEDV IYTWKALGQA ANESHNGSIL PISWRWGESD MTFICVARNP  
201 VSRNFSSPIL ARKLCEGAAD DPDSS HP humanIgG1 H-CH2-CH3

**Bold-** Predicted signal sequence, which will be cleaved in mature protein HP - junction sequence resulting from the BamH1 enzyme site.


**FIGURE 10**

**Peptides in APEX-2mIg**

1 **MAVSRAPTPD** **SACQRMVWLF** **PLVFCLGSGS** EVSQSSSDPQ LMNGVLGESA  
51 VLPLKLPAGK IANIIIWNYE WEASQVTALV INLSNPESPQ IMNTDVKKRL  
101 NITQSYSLQI SNLTMADTGS YTAQITTKDS EVITFKYILR VFERLGNLET  
151 TNYTLLLENG TCQIHLACVL KNQSQTVSVE WQATGNISLG GPNVTIFWDP  
201 RNSGDQTYVC RAKNAVSNLS VSVSTQSLCK GVLTNPPW HP - murine  
IgG2a H-Ch2-CH3

**Bold-** Predicted signal sequence, which will be cleaved in the mature protein HP - junction sequence resulting from the BamH1 enzyme site.

**FIGURE 11**



**FIGURE 12**




FIGURE 13

**Apex1 Antibody Panel**

Reduced



Non reduced




FIGURE 14

**FLAG-APEX-1**

**MPMGSLOPLATLYLLGMLVASCLG****DYKDDDDK****SGPVKELVGSVGGAVTFP**  
LKSKVKQVDSIVWTFNTTPLVTIQPEGGTIIVTQNRNRERVDFPDGGYSLKLSKLKKNDS  
GIYYVGIYSSSLQQPSTQEYVLHVYEHLSKPKVTMGLQSNKNGTCVTNLTCMEHGEEVD  
IYTWKALGQAANESHNGSILPISWRWGESDMTFICVARNPVSRNFSSPILARKLCEGAAD  
DPDSSMVLCLLLVPLLLSLFVLGLFLWFLKRERQEYIEEKRRVDICRETPNICPHSGE  
NTEYDTIPHTNRTILKEDPANTVYSTVEIPKKMENPHSLLTMPDTPRLFAYENVI\*

**MPMGSLOPLATLYLLGMLVASCLG** sequence from human CD5 signal peptide,  
**DYKDDDDK** is the FLAG peptide

**FIGURE 15**

**FLAG-APEX-2**

~~MPMGSLOPLATLYLLGMLVASCIGDYKDEDDK~~SEVSQSSSDPQLMNGVLGESA  
VLPLKLPAGKIANIIWNWEASQVTALVINLSNPESPQIMNTDVKKRLNITQSYSLQI  
SNLTMA DTGSYTAQITTKDSEVITFKYILRVFERLGNLETTNYTLLLENGTCQIHLACVL  
KNQSQT VSV EQATGNISLG GPNVTIFWDP RNSGDQTYVCRAKNAVSNLSVSVSTQSLCK  
GVL TNPPWNAVWFMTTISIISAVILIFVCWSIHVWKRRGSLPLTSQHP ESSQSTDGPGSP  
GNTVYAQVTRPMQEMKIPKPIKND SMTIYSIVNHSREETVALTGYNQPITLKVNTLINYS\*

MPMGSLOPLATLYLLGMLVASCIG sequence from human CD5 signal peptide,  
DYKDDDDK is the FLAG peptide

**FIGURE 16**